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Abstract 
Septic shock is a complication that affects thousands of patients leading to high mortality 
rates and increased healthcare costs.  One treatment in the attempt to decrease poor 
outcomes is corticosteroids.  A systematic review was conducted to evaluate the impact 
of corticosteroids on mortality in adult patients with septic shock.  Databases searched 
were CINAHL, PubMed, OVID, and Cochrane Library.  A literature review was 
performed and pertinent data from each article was recorded in data collection tables.  A 
total of six articles were critically analyzed.  The Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) checklist and flow diagram were used to guide this 
systematic review.  The Critical Appraisal Skills Programme (CASP) checklist assisted in 
assessing the quality of the articles selected.  Cross study analysis was performed via the 
data collection tables developed by this author.  This analysis revealed five of the six 
trials did not detect a decrease in mortality using corticosteroids in adult patients with 
septic shock; the sixth study did document a reduction in mortality rate.  Four studies 
were underpowered which may affect the generalizability of their outcomes.  Two studies 
were adequately powered with one demonstrating positive outcomes.  Possible benefits 
were seen in the secondary outcomes such as faster resolution of shock and decreased 
vasopressor use.  Advanced practice nurses are having an increased prominent role in 
patient care within healthcare.  This role provides an opportunity for high quality 
evidence-based results to be applied to improve patient care.  Results of this systematic 
review provide information to guide decision making by the advanced practice nurse as 
well as suggestions for further study. 
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The Impact of Corticosteroids on Mortality in Adult Patients with Septic Shock 
Background/Statement of the Problem 
In the United States (US), more than 1.5 million people develop sepsis each year, 
with about 250,000 ultimately dying from the disease process (Center for Disease Control 
[CDC)], 2017).  In addition, sepsis is the most expensive condition in hospitals, 
accounting for $20.3 billion in the US in 2011 (Pfuntner, Weir, & Steiner, 2013).  Singer 
et al. (2016) indicated that even with advanced medical technologies such as vaccines, 
antibiotics, and acute care, sepsis is the leading cause of death from infection.  Sepsis can 
progress into its most severe form, septic shock, defined as a “dysregulation of the host 
response to infection, with circulatory, cellular, and metabolic abnormalities” (Annane et 
al., 2018, p. 809).   
The typical treatment regimen of septic shock includes intravenous fluids, 
antibiotics, and vasopressors.  This regimen has remained largely unchanged over the last 
several years.  The Surviving Sepsis Campaign first introduced guidelines in 2004, with 
the goal of decreasing mortality from sepsis by 25% in five years.  Although the initial 
goal was not met, there were improvements in mortality rates, with some hospitals 
experiencing a 20% decrease in mortality (Melville, Ranjan, & Morgan, 2015).  Since the 
first set of guidelines, three revisions have been made as new research is published.  In 
addition to fluids, antibiotics, and vasopressors, the organization makes recommendations 
on adjunctive treatment options such as albumin, immunoglobulins, blood products, and 
corticosteroids (Rhodes et al., 2017). 
Corticosteroids are typically used as adjunctive in the treatment of septic shock.  
The theory behind administering corticosteroids is that patients experience adrenal 
insufficiency when critically ill and therefore, will benefit from an exogenous source 
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such as intravenous steroids (Gupta & Ba, 2008).  Despite this theory, there have been 
conflicting results involving their use in septic shock.  Lv, Gu, Chen, Yu, and Zeng 
(2017) affirmed that controversies on the association between corticosteroids and 
mortality in patients with septic shock exist.  Studies may exhibit considerable variability 
in mortality due to the time frame between the onset of septic shock and the initiation of 
corticosteroid therapy (Lv et al.).  Furthermore, the Surviving Sepsis Campaign suggested 
a daily dose of 200mg IV hydrocortisone if adequate fluid resuscitation and vasopressor 
therapy are not able to restore hemodynamic stability, although it must be noted that this 
is a weak recommendation with a low quality of evidence (Rhodes et al.).  The Surviving 
Sepsis Campaign stated the low quality of evidence stems from contradictory results from 
prior studies, in which some have exhibited a reduction in mortality rates while others 
have demonstrated no difference in mortality (Rhodes et al.).   
Since the latest publication of the Surviving Sepsis Campaign in 2016, recent 
studies, including randomized control trials, have been published that may provide new 
evidence on the effects of corticosteroids on mortality in adult patients with septic shock.  
Therefore, the purpose of this paper is to conduct a systematic review to examine whether 
the use of corticosteroids in septic shock impacts overall mortality in adult patients. 
A review of the literature will be presented in the next section. 
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Literature Review 
 
 The databases searched include PubMed, CINAHL, and OVID.  Articles from 
2000 to 2018 were included in the search.  The keywords used to find relevant literature 
included corticosteroids, steroids, sepsis, septic shock, hypothalamic-pituitary-adrenal 
axis, and mortality. 
Sepsis 
 Sepsis is a very common diagnosis in hospitals, and if undertreated or mistreated, 
can cause multi-organ failure and possibly death.  Healthcare providers encounter sepsis 
frequently and recognition of sepsis and initiating treatment in a timely manner are 
necessary to provide the best chance for survival (László, Trásy, Molnár, & Fazakas, 
2015).  An understanding of the pathophysiology of sepsis should be achieved to better 
treat this disease process.   
 Definition and Pathophysiology.  The most recent definition of sepsis by the 
Third International Consensus Definitions Task Force (Sepsis-3) is defined as a “life-
threatening organ dysfunction caused by a dysregulated host response to infection” 
(Singer et al., 2016, p. 2).  Sepsis begins when the body’s localized defenses can no 
longer defend itself from an external insult.  Normally, the human body experiences a 
myriad of attacks on its immune system daily and can fight its way back to a normal state 
even when its primary defenses have been penetrated.  László et al. (2015) stated that 
these processes are well regulated and maintain an even balance that keep the 
inflammatory response localized.  When an attack overwhelms the body’s localized 
defenses, the body reacts with a systemic inflammatory response to fight the infection.  
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This dysregulated and unbalanced response affects the entire body and starts impairing 
the function of vital organs (László et al.).   
Sepsis may develop from an infectious or non-infectious process.  The infectious 
process could be caused by a bacterial, viral, or fungal source, whereas the non-infectious 
process can occur from the inflammatory response of ischemia or muscle damage caused 
by severe trauma, surgery, myocardial infarction, burns, or acute pancreatitis (Steen, 
2009).  
Diagnosis.  Unlike many other diseases and conditions, there is no single 
diagnostic test to diagnose sepsis.  Sepsis requires the recognition of several factors to be 
properly diagnosed.  In intensive care units, the Task Force, assembled by the European 
Society of Intensive Care Medicine and the Society of Critical Care Medicine, 
recommended using the Sequential Organ Failure Assessment (SOFA) instrument to 
identify patients with organ dysfunction (Singer et al., 2016).  The Sequential Organ 
Failure Assessment measures mortality risk although it can be used to clinically 
characterize a septic patient (Singer et al.).  This instrument examines assessment data 
such as creatine, bilirubin, platelet levels, Pa02 and Fi02 ratios, mean arterial pressure 
(MAP), and the Glasgow Coma Scale with a score ≥2 indicating organ dysfunction.  A 
new measure, called the quick SOFA (qSOFA) uses assessment data of mentation, 
systolic blood pressure, and respiratory rate and is a simpler instrument to identify 
patients with suspected infection who are likely to have poor outcomes (Singer et al.).  A 
positive qSOFA is an indicator for healthcare providers to investigate for organ 
dysfunction, begin therapy, and consider a higher level of care with more frequent 
monitoring (Singer et al.).  
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Shock 
 The first classification system of shock was devised by the surgeon Alfred 
Blalock in 1934 in which he categorized shock into four types: hypovolemic, cardiogenic, 
neurogenic, and vasogenic (septic shock).  As research evolved, a new classification 
system, based on cardiovascular characteristics, was created by Hinshaw and Cox in 1972 
that deemed septic shock as a form of distributive shock (Funk, Parrillo, & Kumar, 2018).   
Shock is defined as “a life-threatening condition categorized by inadequate 
delivery of oxygen and nutrients to vital organs relative to their metabolic demand” 
(Strehlow, 2010, p. 57).  The body is in a state in which there is insufficient energy to 
keep up with its requirements to function properly.  There are different types of shock, 
which include hypovolemic, cardiogenic, anaphylactic, neurogenic, and septic shock.  
Many of these types of shock are characterized by common symptoms.  The early signs 
typically include tachypnea, tachycardia, weak or bounding peripheral pulses, delayed 
capillary refill, pale or cool skin, oliguria, and lactic acidosis (Stehlow).  Late signs of 
shock consist of central cyanosis, decreased mental status, weak or absent central pulses, 
hypotension, and bradycardia (Stehlow).  Each type of shock has other, more defining 
signs and symptoms that may help clinicians identify and treat the type of shock 
appropriately. 
Septic Shock 
 Septic shock is the most severe form of sepsis.  Singer et al. (2016) defined septic 
shock as “a subset of sepsis in which underlying circulatory and cellular metabolism 
abnormalities are profound enough to substantially increase mortality” (p. 9).  The 
clinical criteria used to identify septic shock are: (1) sepsis; (2) vasopressor therapy 
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needed to elevate MAP ≥65 mmHg; and (3) lactate >2mmol/L (18mg/dL) despite 
adequate fluid resuscitation (Singer et al.).  The key variables in septic shock are the need 
for vasopressors and fluid resuscitation to maintain an adequate blood pressure and 
maintain lactate levels less than 2mmol/L.  Failure to recognize septic shock and treat it 
effectively can cause organ damage and death (Singer et al.).   
Effects of Sepsis on the Hypothalamic-Pituitary-Adrenal Axis 
 The human body has defense mechanisms that protect itself from threats 
occurring both inside and outside the body.  The hypothalamic-pituitary-adrenal axis 
(HPA) is comprised of the hypothalamus, pituitary gland, and adrenal glands.  These 
organs interact with each other to create a system that regulates many bodily functions 
such as digestion, the immune system, mood and emotions.  Although all these are 
important functions, the most essential purpose of the HPA axis may be in controlling the 
body’s reaction to stress (Schroeder et al., 2001). 
 When a stressful event occurs, the HPA axis is activated to respond and protect 
the body from its potential harmful effects.  A cascade of actions occurs in this stress 
response.  Corticotrophin-releasing hormone (CRH) is released from the hypothalamus 
and acts on the anterior pituitary to release adrenocorticotrophic hormone (ACTH), which 
stimulates cortisol production and release from the adrenal glands (Gupta & Bhatia, 
2008).  Cortisol is the hormone that is important in fighting stressful events such as 
sepsis.  The adrenal glands are incapable of generating enough cortisol in inflammatory 
states caused by serious diseases (Williams, 2018).  This impairment in HPA axis cortisol 
production in the setting of sepsis may contribute to the body’s difficulty in returning to a 
homeostatic state. 
7 
 
 In a study by Schroeder et al. (2001), the functional integrity of the HPA axis in 
patients with severe sepsis was investigated by simulating the axis through a CRH test.  
The pituitary-adrenal response was examined after the administration of CRH within 24 
hours after diagnosis of severe sepsis and before discharge when patients were without 
signs of sepsis.  The CRH test involved injecting 100 µg of human CRH intravenously, 
once between 8:00am and 9:00am.  Plasma ACTH and cortisol levels were drawn 15 
minutes before the administration of CRH, at the time of administration, then 15, 30, 45, 
and 60 minutes after administration.  Results demonstrated impaired plasma cortisol 
response to a CRH test as well as lower plasma cortisol concentrations in non-survivors 
compared with survivors of severe sepsis.  Schroeder et al. concluded that dysfunction of 
the endocrine system in severe sepsis may be evident through the reduced response to 
CRH stimulation in this sample of patients.  The deficiency in the HPA axis caused by 
sepsis may contribute to mortality in this population. 
Corticosteroids 
 Corticosteroids are a class of hormones that play an integral part in the body’s 
daily functions.  Corticosteroids have the ability to treat allergic and inflammatory 
disorders and suppress unwanted immune system actions (Williams, 2018).  There are 
two types of corticosteroids, glucocorticoids and mineralocorticoids.  Mineralocorticoids 
refer to hormones, such as aldosterone, and are involved in regulating electrolyte and 
water balance in the kidney.  In the clinical setting, the term corticosteroid refers to 
agents with glucocorticoid activity (Williams).  This class contains the endogenous 
cortisol, which as described prior, have immunosuppressive and anti-inflammatory 
effects.  Among others, different types of corticosteroids are used to mimic cortisol 
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including hydrocortisone, dexamethasone, and prednisolone.  Each have their own unique 
onset, peak and duration of action although they all are intended to mimic cortisol’s 
properties of suppressing or preventing undesirable allergic reactions or inflammation 
(Williams). 
 Corticosteroids affect several stages in the inflammatory pathway by diffusing 
across cell membranes and binding to glucocorticoid receptors causing changes in the 
receptor (Williams, 2018).  These changes include decreasing the production of T 
lymphocytes, decreasing activity of natural killer cells, reversing macrophage activity, 
and suppressing synthesis, secretion, and action of chemical mediators in the 
inflammatory and immune response.  These chemical mediators include interleukins, 
prostaglandins, leukotrienes, bradykinin, serotonin, and histamine.  Other mechanisms 
inhibited are those involved in the production of cyclooxygenase-2, nitric oxide synthase, 
and pro-inflammatory cytokines like tumor necrosis factor alpha and various interleukins 
(Williams).  
 Corticosteroids are utilized in many areas of medicine.  One such use is in the 
management of asthma.  Inhaled corticosteroids (ICS) are the most effective therapy in 
maintaining asthma control through its anti-inflammatory effects on the airway 
(Williams, 2018).  Corticosteroid use has been shown to decrease mortality in this 
population (Raissy, Kelly, Harkins, & Szefler, 2013).  Corticosteroids are also used in the 
management of irritable bowel syndrome (IBS).  The role of corticosteroids in IBS is to 
rapidly control symptoms and the acute phase of the disease with their anti-inflammatory 
and immunosuppressive properties (Hall, 2011). 
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 The utilization of corticosteroids in conditions that effect different systems of the 
body creates the possibility of a beneficial use in septic shock.  Williams (2018) stressed 
the acute use of corticosteroids should not be delayed in life-threatening conditions.  
Success in reducing mortality in the management of asthma exacerbations possibly 
supports the potential of corticosteroids in effecting mortality rates in septic shock.   
Septic Shock Treatment and Management Strategies 
 Septic shock, a form of distributive shock, is defined as being “caused by a loss of 
vasomotor control resulting in arteriolar and venular dilation, and after resuscitation with 
fluids, characterized by increased cardiac output and decreased systemic capsular 
resistance” (Funk et al., 2018, p. 96).  The cardiovascular component, along with the 
presence of an infection, forms the basis of treatment and management of septic shock. 
 The treatment of septic shock has remained largely unchanged over the last few 
years despite the latest research and improvements in medicine.  Singer et al. (2016) 
asserted that even with advanced medical technologies such as vaccines, antibiotics, and 
acute care, sepsis leads as the primary cause of death from infection.  The typical 
treatment regimen for septic shock has included antibiotics, fluid resuscitation, and 
vasopressors. 
The most current guidelines in managing septic shock by the Surviving Sepsis 
Campaign include a long list of recommendations that may be used throughout the course 
of septic shock.  The initial guidelines in managing septic shock include: 
1. Application of fluid challenge technique and continued fluid administrations as 
long as hemodynamic factors continue to improve.  Crystalloids are the preferred 
fluid or initial resuscitation and subsequent fluid replacement. 
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2. Administration of IV antimicrobials initiated as soon as possible after 
recognition and within one hour for both sepsis and septic shock. 
3. Norepinephrine is the first vasopressor recommended followed by vasopressin 
and epinephrine.  In some cases, dopamine and dobutamine may be used (Rhodes 
et al., 2017).  
 Fluid Resuscitation. Fluid resuscitation is the first-line therapy in patients who 
are experiencing septic shock.  Hypotension and increased serum lactate levels are signs 
of tissue hypoperfusion and are indicators for the initiation of fluid therapy.  At least 30 
ml/kg of IV crystalloid fluid should be given within the first three hours and additional 
fluids given thereafter to maintain hemodynamic status (Rhodes et al., 2017).  Providing 
this therapy aids in decreasing the chances of organ dysfunction that could lead to further 
deterioration in patients. 
Antibiotics. The initial management strategies are key to survival when a patient 
is presumed to be experiencing septic shock.  The suspected infection needs to be 
addressed by obtaining cultures from body fluids (blood, urine, peritoneal, and other 
sources), beginning broad-spectrum antibiotics, and initiating infectious source control.  
Identifying the source of infection is crucial as without this action treatment would not be 
effective.  Removing the source of infection may consist of removing a device such as a 
peripherally inserted central catheter (PICC), draining an infected fluid such as an 
abscess, or debriding infected tissue as seen in necrotizing pancreatitis.  The broad-
spectrum intravenous antibiotics will provide the necessary treatment against the most 
likely pathogens until exactly identified from obtained cultures (Seymour & Rosengart, 
2015). 
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Vasopressors.  In conjunction with fluid therapy, vasopressors provide additional 
assistance in maintaining adequate tissue perfusion.  Vasopressors are initiated when 
fluid therapy alone is not enough in providing hemodynamic stability.  There are different 
types of vasopressors that have an effect on different parts of the cardiovascular system, 
with the intended action of raising blood pressure to an adequate level.  Norepinephrine 
has been the typical vasopressor of choice and recommended by various guidelines and 
expert opinions (Seymour & Rosengart, 2015).  In addition, vasopressin at a fixed rate 
(0.03-0.04 U/min) in patients with increased norepinephrine requirement is suggested as 
a supplementary medication therapy (Seymour & Rosengart).  These medications, along 
with fluid resuscitation, are important in the treatment and management of septic shock. 
 Adjunctive Treatments.  There are multiple adjunctive therapies that can be used 
to treat septic shock.  In fluid therapy, colloids such as albumin have been used to assist 
with blood pressure control.  Hydroxyethyl starch, another colloid, had previously been 
used as well, although this has been shown to increase rates of renal replacement therapy 
(Seymour & Rosengart, 2015).  Recently, vitamin C has been researched in treating 
sepsis and septic shock.  The anti-oxidant and enzyme cofactor properties of vitamin C is 
thought to reverse sepsis induced organ dysfunction (Marik, 2018); however, the use of 
vitamin C requires more research to be considered part of the septic shock treatment 
regimen.  A more widely used adjuvant is corticosteroids.  The rationale for their use is 
patients experience adrenal insufficiency during sepsis and would benefit from an 
exogenous source such as intravenous steroids. 
Use of Corticosteroids in Septic Shock 
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 Corticosteroids have been used in different areas of medicine for many years.  
Their use in sepsis and septic shock was started soon after an observation by Sir William 
Osler, in the 1900s, who postulated that many suffering from a severe infection were 
more inclined to die from the body’s inflammatory response to the infection rather than 
the infection itself (Salluh & Póvoa, 2017).  This observation, coupled with the fact that a 
patient’s HPA axis is suppressed when critically ill, led medical professionals to utilize 
corticosteroids in septic patients.  Salluh and Póvoa (2017) believe the ability to manage 
the inflammatory response caused by an infection would clinically stabilize patients and 
increase survival rates.  
Many types of studies ranging from as far back to the 1980s were used to support 
the recommendations made by the Surviving Sepsis Campaign.  It is important to note 
that in the 1980s steroids were used more often instead of adequate fluid therapy, early 
initiation of antibiotics, early collection of blood cultures, and lactate monitoring (Salluh 
& Póvoa, 2017).  The use of corticosteroids in septic patients became standard after the 
Surviving Sepsis Campaign released the first guidelines in 2004 (Salluh & Póvoa).  The 
organization’s latest guidelines note that the recommendation related to corticosteroids is 
weak with a low quality of evidence.  Their efficacy in reducing mortality in this specific 
population has been debated.  The Surviving Sepsis Campaign stated their designation of 
low quality of evidence comes from contradictory results from prior studies with some 
exhibiting a reduction of mortality rate while others show no difference in mortality 
(Rhodes et al., 2017).   Lv et al. (2017) supported this and noted controversies on the 
association between corticosteroids and mortality in patients with septic shock exist.  The 
authors mention the possibility of substantial variability in mortality due to the time 
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frame between the start of septic shock and the initiation of corticosteroid therapy (Lv et 
al.).  
 In a prospective observational study conducted by Ferrer et al. (2009), researchers 
analyzed the effectiveness of four treatments including early broad-spectrum antibiotics, 
fluid challenge, low-dose steroids, and drotrecogin alfa.  This later drug, drotrecogin alfa, 
was a recombinant form of human activated protein C that exhibited anti-inflammatory 
effects but has since been withdrawn from the market due to its failure to demonstrate 
survival benefit.  Two thousand seven hundred ninety-six adult patients from 77 intensive 
care units were observed and the primary outcome measured was mortality.  Ferrer et 
al.’s findings indicated there was no association between the administration of low-dose 
steroids in septic shock and mortality.  The effectiveness of each treatment was measured 
using propensity scores: early-broad spectrum antibiotics (odds ratio, 0.67; 95% 
confidence interval (CI), 0.50-0.90, P = 0.008), drotrecogin alfa (odds ratio, 0.59; 95% 
CI, 0.41-0.84, P = 0.004), fluid challenge (odds ratio, 1.01; 95% CI, 0.73-1.39, P = 
0.966), and low-dose steroids (odds ratio, 1.04; 95% CI, 0.85-1.28, P = 0.688).  No risk 
or benefit was found with use of low-dose steroids, but it is important to note that the 
observational design may have limited the results of the study.  The authors revealed the 
possibility of the results being influenced by different patient presentations among the 
intensive care units examined and current trends in septic shock management (Ferrer et 
al.).  
Duane et al. (2014) evaluated the benefit of early low-dose corticosteroid in 
patients with septic shock.  The study included 6,663 patients of whom 1,838 were 
administered a low-dose corticosteroid intravenously within 48 hours of being diagnosed 
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with septic shock and were compared to patients who did not receive low-dose 
corticosteroids.  The primary outcome of 30-day mortality was assessed.  Results showed 
the group that received the corticosteroid therapy was associated with a similar 30-day 
mortality when compared with the group who did not receive corticosteroid therapy 
(35.5% vs 34.9%).  Duane et al. determined early-administration of corticosteroids does 
not decrease mortality in septic shock patients. 
Recent studies, including randomized control trials, have been published since the 
latest recommendations that may provide new evidence on the effects of corticosteroids 
on mortality in adult patients with septic shock.  In addition, the standard of care should 
have been modified since the release of the Surviving Sepsis Campaign’s initial 
guidelines in 2004.  Randomized control trials published after this date may offer 
different evidence than those conducted before release of the guidelines.  These 
randomized control trials will be included in the systematic review. 
Next, the framework that will be used to guide this research will be presented. 
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Theoretical Framework 
The theoretical framework utilized to guide this systematic review will be the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).  The 
aim of PRISMA is to assist authors in generating a clear and comprehensive reporting of 
systematic reviews and meta-analyses.  Systematic reviews and meta-analyses are 
important research in healthcare as they are high level quality studies and can assist 
clinicians in creating evidence based clinical practice guidelines (Moher, Liberati, 
Tetzlaff, Altman, & The PRISMA Group, 2009).  The focus of PRISMA is on 
randomized control trials, but it can also be used in reporting systematic reviews of other 
types of research.  PRISMA consists of a 27-item checklist (Appendix A) and a four-
phase flow diagram (Appendix B).  
The PRISMA checklist pertains to the content of a systematic review and assists 
the researcher in structuring the report in an organized manner.  It summarizes results 
from multiple studies into a single succinct document.  The checklist contains seven 
major headings such as title, abstract, introduction, methods, results, funding and lastly 
includes several sub-headings (Moher et al., 2009). 
The four-phase flow diagram depicts the course of studies through the different 
stages of the systematic review process.  It guides the researcher in the identification and 
selection of studies.  The diagram’s four phases are identification, screening, eligibility, 
and inclusion (Moher et al., 2009).  Identification involves discovering studies or records 
within databases and other sources.  Through use of the databases, the researcher 
combines search terms in different combinations and applies limits such as a specific 
population, years of search, and English language only.  This results in a specific number 
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of studies.  The screening phase is comprised of eliminating duplicate studies, including 
screening the articles for ones that are pertinent to the research question.  The eligibility 
phase entails omitting studies that may not meet specific inclusion and exclusion criteria.  
Finally, the inclusion phase is the final number of studies that will be used in the 
systematic review. 
To assess the quality of articles selected, the Critical Appraisal Skills Programme, 
(CASP) will be used.  The Critical Appraisal Skills Programme enables the researcher to 
systematically assess the trustworthiness, relevance, and results of studies (CASP, 2018).  
This program contains eight critical appraisal tools that can be used in systematic 
reviews, randomized control trials, cohort studies, and others.  The checklist used in this 
research project was the CASP Randomized Control Trial Checklist (Appendix F).  This 
checklist is comprised of 11 questions divided into three sections.  The sections cover 
broad issues such as what the results are, whether they are valid, and if the results will 
help locally (CASP).  Through utilization of this checklist randomized control trials can 
be successfully appraised to create a valid systematic review. 
Next, the methods that will be used to guide the research will be discussed. 
 
  
17 
 
Method 
 
Purpose 
 The purpose of this systematic review was to examine whether the use of 
corticosteroids, in septic shock, impacts overall mortality in adult patients.  Outcomes 
examined included corticosteroid administration compared to no corticosteroid 
administration in the management of septic shock on mortality rates.  The research 
question examined was: Does the administration of corticosteroids in septic shock 
decrease mortality in adult patients? 
Inclusion/Exclusion Criteria 
 Inclusion criteria included randomized control trails published from 2008 to 2018.  
Studies must have included participants 18 years of age or older and experiencing septic 
shock.  Studies must have been peer reviewed and written in the English language.  
Lastly, studies must have compared the administration of corticosteroids to no 
corticosteroids for the treatment of septic shock and impact on mortality rates.  Exclusion 
criteria were articles published prior to 2008, participants less than 18 years old, non-
English language articles, and articles that were not randomized control trials. 
Search Strategy 
 A comprehensive search was conducted using the CINAHL, PubMed, OVID, and 
Cochrane Library databases.  Keywords used included sepsis, septic shock, 
corticosteroids, steroids, and mortality. 
Using the PRISMA four-phase diagram, studies were identified, screened for 
duplicates, and assessed for eligibility, which resulted in a select number of studies to be 
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used in the systematic review.  This provided transparency and ensured a careful 
selection of studies necessary to conduct the systematic review (Moher et al., 2009). 
Data Collection  
 Two data collection tables, created by the author of this paper, was used to collect 
and organize information extracted from the selected studies.  Data collected in Table 1 
included the studies’ purpose, design, sample, mortality endpoint, and corticosteroid used 
and dose.  Table 2 included any identified placebo (no corticosteroid), mortality rate, key 
findings, and limitations.  Organizing data into these tables ensured a clear means of 
assessing and examining significant information from each study.   
Table 1. 
Data Collection Tool 1 
 
Table 2. 
Data Collection Tool 2 
 
 
Study: 
Purpose Study Design Sample 
Demographics 
Mortality Endpoint Corticosteroid 
Study: 
Identified Placebo Mortality Rate Key Findings Limitations 
Corticosteroid Placebo              
(No corticosteroid) 
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Critical Appraisal  
 The quality of the studies was assessed using the Critical Appraisal Skills 
Programme (CASP) Randomized Control Trial Checklist.  As described in the theoretical 
framework section, this 11-question tool validates the results of each trial, assesses the 
preciseness of treatment results, and considers clinically important outcomes (CASP, 
2018).  This checklist guarantees the selected studies are of the highest quality.  Each 
study was appraised and their results reported. 
Cross Analysis 
Once the studies have been critically appraised, a cross-study analysis was 
conducted.  The information was recorded in a table created by the author to evaluate the 
similarities and differences regarding the impact of corticosteroids on mortality in 
patients’ experiencing septic shock (Table 3).  
Table 3. 
Cross Analysis 
Author, 
Year 
Mortality Rate 
at Day 28 
Resolution of 
Shock 
Vasopressor 
Usage 
Length of Stay (LOS) 
ICU Hospital 
         
Next, the results of the systematic review will be discussed. 
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Results 
 The PRISMA flowchart (Appendix B) and the inclusion/exclusion criteria were 
used to select articles that were applicable for this systematic review.  The breakdown of 
the search strategy is depicted in Appendix C.  The original search terms ceded 237 
results. After eliminating duplicate articles, there were 165 remaining for review.  The 
titles and abstracts were evaluated to determine appropriateness looking specifically for 
inclusion and exclusion criteria.  This yielded 18 articles.  The full-text of these articles 
were read and again, inclusion and exclusion criteria used, to decide if they could be 
applied for this review.  A total of six articles remained and were used in this systematic 
review.  Key information was extracted and inputted onto the data collection tables in 
Appendices D and E.  After analyzing the obtained articles’ data, each study was 
summarized as shown in the following section.  The studies are presented in 
chronological order.  In addition, the studies were critically appraised using the CASP 
checklist (Appendix F). 
 The randomized control trial conducted by Sprung et al. (2008) (Appendices D1 
& E1) evaluated the efficacy and safety of low-dose hydrocortisone in patients with 
septic shock.  Patients were enrolled from March 2002 to November 2005 at 52 ICUs in 
nine countries.  Enrollees needed to be 18 years or older, have clinical evidence of 
infection and a systemic response to the infection, an onset of shock within the previous 
72 hours, and hypoperfusion or organ dysfunction related to sepsis.  Excluded were those 
who had an underlying disease with a poor prognosis, a life expectancy of less than 24 
hours, immunosuppression, and treatment with long-term corticosteroids within the past 
six months or short-term corticosteroids within the last four weeks.  Of the 500 patients 
enrolled, one withdrew consent.  The rest were divided into two groups: the 
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hydrocortisone group and placebo group.  The 251 participants in the hydrocortisone 
group had a mean age of 63 + 14 years with a mean SOFA score of 10.6 + 3.4.  The 
group was 66% male.  The 248 participants in the placebo group had a mean ago of 63 + 
15 with a mean SOFA score of 10.6 + 3.2 consisting of 67% male gender.  The study’s 
main endpoint was death at 28 days in patients who did not have a response to 
corticotropin.  Other endpoints were death at 28 days in patients with a corticotropin 
response, mortality rate in the hospital, ICU, and overall.  Also, the rate of shock reversal, 
and length of stay (LOS) in the ICU and hospital were assessed.  The study drug, 
hydrocortisone, was given intravenously as a 50 mg bolus every 6 hours for 5 days, then 
every 12 hours for days 6 to 8, every 24 hours for days 9 to 11, and then stopped.  Vials 
containing placebo were given in the same manner. 
 The study revealed (Appendix E1) there was no significant difference between the 
two groups in the rate of death at 28 days among overall patients and those with and 
without a response to corticotropin (P=0.51).  Overall, 34.3% of the hydrocortisone group 
died while 31.5% of the placebo group died.  In those with no corticotropic response, 
39.2% of the hydrocortisone group and 36.1% of the placebo group died whereas 28.8% 
of the hydrocortisone group and 28.7% of the placebo group died in those with a 
corticotropin response.  The hospital and ICU discharge 28-day mortality were similar in 
both groups.  The reversal of shock was similar among both groups as well.  In terms of 
median time until reversal of shock, the hydrocortisone group experienced a shorter time 
of 3.3 days while the placebo group required 5.28 days.  The LOS was similar in both 
groups for both in hospital and in ICU.  Lastly, the hydrocortisone group experienced 
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more adverse events such as an increased rate of superinfections, hyperglycemia, and 
hypernatremia. 
 Critical analysis of the Sprung et al. (2008) study using the CASP checklist 
(Appendix F1) revealed a less precise treatment effect due to a sample size of 500 instead 
of the 800 patients needed the achieve a statistical power of 80%.  Also, one patient was 
not accounted for at the end of the trial due to withdrawal of consent after randomization.  
Some patients did openly receive corticosteroids after enrollment due to allergic 
reactions, laryngeal edema, bronchospasm, brain edema, replacement of long-term 
corticosteroid therapy whose history was unknown at enrollment, acute respiratory 
distress syndrome, and septic shock.  This rate was similar among the hydrocortisone and 
placebo group at 4.4% and 4.0%, respectively. 
The study conducted by Arabi et al. (2010) (Appendices D2 & E2) examined the 
effect of low-dose hydrocortisone in patients with cirrhosis who presented with septic 
shock.  The study was a randomized double-blind placebo-controlled trial conducted at a 
900-bed tertiary care academic hospital on a 21-bed medical-surgical ICU.  Patients 
enrolled required to be aged 18 years or older with liver cirrhosis who presented with 
septic shock within 72 hours of the onset of hypotension.  Patients were excluded if there 
was evidence of hemorrhagic shock, known adrenal insufficiency, any prior systemic 
steroid usage, contraindications for systemic steroids, post-cardiac arrest, and do-not-
resuscitate status.  Of the 140 patients that were screened, 75 were enrolled and randomly 
allocated into two groups.  The hydrocortisone group was 44% female with a mean age of 
60.6 + 12.6 and mean SOFA score of 14.6 + 3.7.  The placebo group was also 44% 
female with a mean age of 59.3 + 12.2 and mean SOFA score of 14.3 + 3.7.  The primary 
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endpoint of this study was 28-day all-cause mortality and secondary outcomes included 
ICU and hospital mortality at 28 days, shock reversal, and vasopressor-free days.  
Patients received intravenous bolus injections every six hours of either 5mL of 50 mg of 
hydrocortisone or placebo.  This was given until shock resolved which was defined as a 
stable blood pressure (MAP>65) without a vasopressor for 24 hours.  At this point, the 
dose was reduced by 1 mL every 2 days until discontinued. 
Results of this study (Appendix E2) demonstrated no significant difference 
between the hydrocortisone and placebo groups in 28-day mortality (P=0.19).   Deaths in 
the hydrocortisone group accounted for 85% of the patients while the placebo group 
encountered 72% deaths.  The ICU (P=0.86) and hospital LOS (P=0.90) were similar in 
both groups.  Mortality was also similar in both groups in the ICU and hospital (P=0.64 
and P=0.82, respectively).  ICU mortality was 62% and 67% in the hydrocortisone and 
placebo group, respectively.  Hospital mortality was 87% in those receiving 
hydrocortisone and 89% in those receiving placebo.  The hydrocortisone group did show 
some improvement in hemodynamic parameters.  There were more patients in the 
hydrocortisone group who experienced shock reversal (62%, P=0.05) and more 
vasopressor-fee days (6.8 days, P=0.54) than the placebo group (39% and 5.6 days).  
When looking at adverse events, severe hyperglycemia and gastrointestinal bleeding was 
more prevalent in patients receiving hydrocortisone.  There existed some limitations in 
this study such as the single center setting that could affect generalizability.  Others 
included the long length of randomization of 72 hours and the use of etomidate in some 
patients that has been proven to cause adrenal suppression. 
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Upon critical appraisal of the Arabi et al. (2010) study (Appendix F2), the CASP 
checklist revealed that the groups were not treated equally.  There were five patients in 
the placebo group that ended up receiving corticosteroid therapy due to life-threatening 
hypotension.  Because of this, they were moved to the other study arm and considered 
crossovers.  Also, blinding was opened for one patient at the primary physician’s request, 
but the therapy was continued as planned.  Despite these factors, the trial did clearly 
address the focused issue, groups were similar at the start of the trial, and all the patients 
were accounted for at the trial’s conclusion.  Although 150 patients were required, 
allocation of patients was stopped at 75 after a planned interim analysis revealed it was 
unlikely that a treatment benefit would be evident if it were completed to the targeted 
sample size.      
In the study by Gordon et al. (2014) (Appendices D3 & E3), researchers tested for 
an interaction between vasopressin and corticosteroids in septic shock.  The study was a 
prospective open-labeled randomized controlled trial conducted between October 2009 
and March 2012 at four adult ICUs in London teaching hospitals.  Inclusion criteria 
consisted of adult patients greater than 16 years old who had sepsis requiring 
vasopressors despite intravenous fluid administration.  There were many exclusion 
criteria as described in the appendix that included patients who received a previous 
continuous infusion of vasopressors during the current hospitalization, had an ongoing 
requirement for systemic steroids, death anticipated within 24 hours, or enrollment in 
another trial that may interact with study drugs.  Sixty-one patients were assigned to one 
of two groups: hydrocortisone or placebo.  All patients received vasopressin and either 
hydrocortisone or placebo once the vasopressin was titrated to 0.06 U/min.  The 
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hydrocortisone group comprised of 58% males with a mean age of 61 and APACHE II 
score of 19 while the placebo group was 60% male with a mean age of 60 and APACHE 
II score of 20.  The primary outcome of this study was the difference in plasma 
vasopressin concentration between the two groups.  Secondary outcomes included 
difference in vasopressin requirements and 28-day, ICU, and hospital mortality.  
Hydrocortisone was given as a 50 mg IV bolus every 6 hours for 5 days, every 12 hours 
for 3 days, and then once daily for 3 days.  The placebo (0.9% saline) was given in the 
same way as the study drug. 
The primary outcome of plasma vasopressin levels was found to be no different 
between the two groups (64 pmol/L difference at 6 to 12-hour time point, 95% CI, -32 to 
160 pmol/L) (Appendix E3).  There was also no difference in mortality rates.  The 28-day 
mortality was 23% in the hydrocortisone group and 23% in the placebo group (-0.01;  
-0.22, 0.20).  ICU mortality in the hydrocortisone group was also 23% while 27% of the 
placebo group died (-0.04; -0.26, 0.18).  Hospital mortality was 26% in the 
hydrocortisone group and 30% in the placebo group (-0.04; -0.27, 0.18).  The value in 
parentheses is the difference in proportions (vasopressin and hydrocortisone minus 
vasopressin and placebo) and 95% CI.  In terms of vasopressin requirements, the 
hydrocortisone group was weaned off of the vasopressor more quickly, having a 3.1 days 
shorter duration and halving the total dose requirement than the placebo group (P=0.001).  
Limitations to this study included the small number of participants which has limited 
power to detect differences in clinical outcomes.  The trial was powered to detect a 
difference in plasma vasopressin levels after reaching a maximum rate of vasopressin and 
corticosteroid administration.  Some patients received norepinephrine first as suggested 
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by the Surviving Sepsis Campaign guidelines.  These patients were weaned off this 
vasopressor and started on vasopressin although not all patients reached the maximum 
rate which reduced the sample size and potential power. 
Critical appraisal of the Gordon et al. (2014) study (Appendix F3) showed similar 
group demographics and randomization of patients to the two groups.  There were two 
factors that prevented the two groups from being treated equally.  First, due to emergent 
situations not all patients received vasopressin as the initial vasopressor.  This accounted 
for 30% of the study participants who were transitioned over to vasopressin to be 
included in the trial.  Second, 11 patients did not reach the maximum vasopressin 
requirements so did not receive the study drug.  In addition, there were five crossovers 
from the placebo group to the hydrocortisone group due to refractory shock although 
researchers claim the results remained unchanged. 
 The Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. study (2017) (Appendices D4 & 
E4) examined 118 patients with septic shock.  The study took place from September 2015 
to September 2016 on a 35-bed ICU of the Subei People’s Hospital.  The aim was to 
assess the importance of early initiation of low dose hydrocortisone.  The inclusion 
criteria consisted of having an age of 18 years or older and the onset of septic shock 
beginning within six hours.  Exclusion criteria was receiving corticosteroid therapy 
within the last three months, high-dose steroid therapy, presence of immunosuppression, 
and refusal of the attending staff or patients’ family.  Patient demographics comprised of 
a 70/48 male-to-female ratio.  Study participants were divided into two groups: the 
hydrocortisone group and the placebo group.  The hydrocortisone group had a mean age 
of 68.8  + 12.6 years and the placebo group was 64.8 + 16.7 years.  The mean SOFA 
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score for the hydrocortisone group was 11.9 + 3.3 and the placebo group was 9.9 + 3.0.  
The intervention comprised of administering 200 mg/dl of hydrocortisone as a continuous 
infusion for six days and then tapering it off.  Once all vasopressors were discontinued, 
the taper protocol was initiated: half dose for five days, then quarter dose for three days, 
then stopped.  The placebo was normal saline which was administered in the same 
manner as the hydrocortisone. 
The results of this study (Appendix E4) showed that there were no significant 
differences in 28-day or hospital all-cause mortality, length of stay (LOS) in the intensive 
care unit (ICU), or hospital between patients treated with hydrocortisone or placebo.  
Both the 28-day and hospital all-cause mortality was 39.7% in the hydrocortisone group 
and 31.7% in the placebo group.  There was a significance level of P=0.365 in both 
categories.  LOS in the ICU was 10.9 + 17.5 days in the hydrocortisone group while the 
placebo group experienced 10.2 + 13.1 days with a significance level of P=0.799.  LOS 
in the hospital was 23.7 + 36.8 days for the hydrocortisone group and 21.7 + 21.7 days 
for the placebo group with a P=0.711 significance level.  Early administration of 
hydrocortisone enabled earlier titration off vasopressor therapy.  Here, the hydrocortisone 
group experienced 2.5 + 2.4 days of vasopressor while the placebo group had 2.8 + 4 
days (P=0.639).  In conclusion, the study demonstrated no decrease in the risk of 
mortality or the length of stay in the ICU or hospital with early administration of low-
dose hydrocortisone in adults with septic shock.  The findings do not support the use of 
hydrocortisone in this population. 
The critical appraisal of this study (Appendix F4) shows the two groups were not 
similar at the start of the trial.  The hydrocortisone group started off with a statistically 
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significant (P<0.001) SOFA score that was higher than the placebo group.  Also, the 
study recruited a small number of patients.  The authors pointed out the study was likely 
to be underpowered to detect a significant difference by the recruitment of patients with 
lower mortality.  Despite this, the placebo-controlled, randomized design of the trial 
contributes to the validity of the study. 
In the Venkatesh et al. (2018) (Appendices D5 & E5) study, the authors examined 
whether hydrocortisone reduces mortality among patients with septic shock.  This study 
recruited a total of 3,800 patients from March 2013 through April 2017.  The patients 
underwent randomization at 69 med-surg ICUs.  The authors compared intravenous 
infusions of hydrocortisone with placebo in patients with septic shock who were 
undergoing mechanical ventilation in the ICUs.  Inclusion criteria required patients to be 
older than 18 years of age, on mechanical ventilation, a documented suspicion of 
infection, met >2 criteria of the systemic inflammatory response syndrome, and treatment 
with vasopressors or inotropic agents for a minimum of 4 hours up to the time of 
randomization.  The criteria excluding patients from this study were those who were 
likely to receive steroids for an indication other than septic shock, had received 
etomidate, were considered to likely die from a pre-existing condition within 90 days, 
had treatment limitations in place, or had met all the inclusion criteria for more than 24 
hours.  Of the 3,800 patients randomized, 3,658 were included in the study and were split 
into two groups: 1,823 in the hydrocortisone group and 1,826 in the placebo group.  The 
mean age of the hydrocortisone group was 62.3 + 14.9 years and the placebo group 62.7 
+ 15.2 years.  There were 60.4% males in the hydrocortisone group and 61.3% in the 
placebo group.  The median APACHE II score was 24.0 in the hydrocortisone group 
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while the placebo group had a score of 23.0.  The primary outcome of the study was 
death from any cause at 90 days.  A secondary outcome was death from any cause at 28 
days.  The intervention group received 200mg of hydrocortisone per day via a continuous 
intravenous infusion over a period of 24 hours for a maximum of seven days or until 
discharge from the ICU.  The control group received placebo in the same manner as 
described. 
The results of this study (Appendix E5) demonstrated that septic shock patients 
undergoing mechanical ventilation with a continuous hydrocortisone infusion did not 
experience a lower 90-day mortality than placebo.  The hydrocortisone group had a 
27.9% mortality rate while the placebo group was 28.8% (P=0.50).  The mortality rate at 
28 days did not differ as well between the hydrocortisone and placebo group with rates of 
22.3% and 24.3%, respectively (P=0.13).  In terms of resolution of shock, it took the 
hydrocortisone group 3 days and the placebo group 4 days to resolve shock (P<0.001).  
Patients receiving hydrocortisone had a shorter time to ICU discharge needing 10 days 
whereas the placebo group required 12 days (P<0.001).  The authors noted some 
limitations to the trial including the inability to decide on the appropriateness of 
prescribed antibiotic therapy and the inability to arbitrate the judgement of the treating 
clinicians on adverse effects related to the study.  Lastly, data on all possible secondary 
infections were not collected. 
The critical appraisal (Appendix F5) of the Venkatesh et al. (2018) study revealed 
not all patients were accounted for at the end of the trial.  This was due to 114 patients 
withdrawing or not having informed consent.  Also, 28 patients were lost to follow-up.  
Regardless of this, the large number of patients provided the study with validity.  The 
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3,800 originally recruited provided the trial with 90% to detect an absolute difference of 
5% in 90-day all-cause mortality. 
Annane et al. (2018) (Appendices D6 & E6) conducted a randomized control trial 
involving 1,241 patients experiencing septic shock to evaluate the effect of 
hydrocortisone and fludrocortisone versus placebo.  The trial was conducted from 
September 2008 to June 2015 at 34 hospitals.  Participants were required to have septic 
shock for less than 24 hours.  Those excluded from the study had septic shock for at least 
24 hours, a high risk of bleeding, pregnancy or lactation, underlying conditions that could 
affect long-term survival, or previous treatment with corticosteroids.  Participants were 
divided into two groups.  The hydrocortisone/fludrocortisone group was 65.5 % male 
with a mean age of 66 + 14 and a SOFA score of 12 + 3.  The placebo group was 67.7% 
male with a mean age of 66 + 15, and a SOFA score of 11 + 3.  The study’s primary 
outcome was 90-day all-cause mortality.  Secondary outcomes included all-cause 
mortality at ICU discharge, hospital discharge, and day 28, and vasopressor free days by 
day 28.  The method entailed administering a 50mg bolus of hydrocortisone 
intravenously every 6 hours and 50µg of fludrocortisone via a nasogastric tube once daily 
every morning.  This was given for seven days without tapering.  The respective placebos 
were given in the same manner. 
The main results of the study revealed a 0.88 relative risk of death (95% CI, 0.78 
to 0.99) in support of the hydrocortisone/fludrocortisone group.  The 90-day all-cause 
mortality rate was 43% for this group while the placebo group saw a rate of 49.1% 
(P=0.03).  In terms of 28-day mortality, there was a 33.7% rate in the intervention group 
while the placebo group saw a 38.9% rate P=0.06).  Mortality was also significantly 
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lower in the hydrocortisone and fludrocortisone group compared to placebo group at ICU 
discharge, 35.4% vs 41% (P=0.04), and hospital discharge, 39% vs 45.3% (P=0.02).  
Also, the intervention group witnessed 17 + 11 vasopressor-free days by day 28 while the 
placebo group had 15 + 11 days (P<0.001).  A key finding that surfaced from the study 
was the increased incidence of hyperglycemia in the hydrocortisone and fludrocortisone 
group although the risk of secondary infection, GI bleeding, and neurological events were 
similar in both groups.  The authors did not declare any limitations in this study. 
Critical analysis of the Annane et al. (2018) study using CASP (Appendix F6) 
found the study met all criteria.  The trial had a precise estimate of the treatment effect.  
Researchers determined 320 patients were needed in each group to detect an absolute 
difference of 10% in 90-day mortality.  The study was able to recruit a total of 1,241 
patients or about 620 patients in each group. 
Cross Analysis 
 The randomized control trials described were compared and analyzed using the 
data collection tables in Appendices D1-6 and E1-6.  The tables tracked important data 
such as mortality rates, the primary objective of this paper, as well as other common data 
like resolution of shock, vasopressor-free days, and LOS in the ICU and hospital. These 
results were recorded in Appendix G for cross analysis.  Adverse events that occurred in 
the studies will also be analyzed. 
 Participants in all six studies had similar mean ages, gender percentage, and 
illness severity using the Sequential Organ Failure Assessment (SOFA) and Acute 
Physiology and Chronic Health Evaluation (APACHE II) scores.  Mean ages ranged 
between 59.3 and 68.8 years and the male gender represented 56-67% of study 
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participants among all the studies.  Sequential Organ Failure Assessment scores ranged 
from 9.0 to 14.6 in the Sprung et al. (2008), Arabi et al. (2010), Lv et al. (2017), and 
Annane et al. (2018) studies and APACHE II scores ranged from 19 to 24 in the Gordon 
et al. (2014) and Venkatesh et al. (2018) studies which all indicate a high mortality 
prediction.  The Arabi et al. (2010) study used only patients with liver cirrhosis.  This 
may have led to the high mortality rate among all the studies.  Despite this, there was still 
no significant difference in 28-day mortality between the two study groups, with the 
hydrocortisone group having an 85% rate and the placebo group a 72% rate (P=0.19.)  
The Venkatesh et al. (2018) study included only mechanically ventilated patients within 
their participants whereas the other studies did not exclude non-ventilated participants.  
This study also specifically excluded patients who had received etomidate as it was noted 
the drug has adrenal-suppressant properties.  All other studies did not exclude patients 
who received this drug.  In the end, mortality rates remained similar, with the 
hydrocortisone group exhibiting a 22.3% rate and placebo group a 24.3% rate (P=0.13). 
Five of the six randomized control trials, Sprung et al. (2008), Arabi et al. (2010), 
Gordon et al. (2014), Lv et al. (2017), and Venkatesh et al. (2018), showed there was no 
significant difference between corticosteroid and placebo groups in 28-day mortality 
(Appendix G).  Only one randomized control trial, the Annane et al. (2018) study, 
showed a decrease in mortality at day 28 in the corticosteroid group compared to the 
placebo group.  Here, the mortality at day 28 was 33.7% for the corticosteroid group and 
38.9% for the placebo group (P=0.06). 
There were some variances among the studies in terms of the secondary 
endpoints.  In terms of resolution of shock, there was faster shock reversal in the 
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corticosteroid group in the Arabi et al. (2010) and Venkatesh et al. (2018) studies.  Arabi 
et al. (2010) showed 62% of patients in the corticosteroid group demonstrated resolution 
of shock compared to 39% in the placebo group (P=0.05).  In the Venkatesh et al. (2018) 
study, shock resolved one day earlier in the corticosteroid group (P=<0.001).  There were 
no differences in reversal of shock the Sprung et al. (2008) study (79.7% vs 74.2%) and 
in the Lv et al. (2017) study (65.6% vs 70.0%, P=0.602).  However, the median time until 
reversal of shock was shorter in the corticosteroid group in the Sprung et al (2008) study:  
3.3 days in the corticosteroid group compared to 5.28 days in the placebo group.  The 
other studies did not report this endpoint.   
Four studies, Arabi et al. (2010), Gordon et al. (2014), Lv et al. (2017), and 
Annane et al. (2018), exhibited more vasopressor-free days or less days on a vasopressor 
in the hydrocortisone group than the placebo group.  The most significant result was in 
the Gordon et al. (2014) study in which the corticosteroid group demonstrated a 3.1day 
shorter duration of vasopressor therapy than the placebo group (P=0.001).  The Lv et al. 
(2017) study had the corticosteroid group on 2.5 + 2.4 days of vasopressor whereas the 
placebo group was 2.8 + 4 days (P=0.639).  Arabi et al. (2010) reported 6.8 vasopressor-
free days in the corticosteroid group versus 5.6 days in the placebo group (P=0.54).  The 
study by Annane et al. (2018) reported that the corticosteroid group had 17 + 11 
vasopressor-free days compared to 15 + 11 days in the placebo group (P<0.001).  The 
remaining two studies did not report this secondary endpoint.   
There was no difference in LOS in the ICU or hospital in the Sprung et al. (2008), 
Arabi et al. (2010), and Lv et al. (2017) studies.  Venkatesh et al. (2018) reported a 
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shorter time to ICU discharge in the hydrocortisone group (P<0.001).  This secondary 
endpoint was not reported by Gordon et al. (2014) or Annane et al. (2018). 
The most common adverse event attributed to the use of corticosteroids was 
hyperglycemia.  This was documented in the randomized control trials by Sprung et al. 
(2008), Arabi et al. (2010), Venkatesh et al. (2018), and Annane et al. (2018).  Other 
more prominent adverse events included superinfection and hypernatremia in Sprung et 
al. (2008) as well as gastrointestinal bleeding in Arabi et al. (2010).  The Lv et al. (2017) 
study did not report adverse events and the study by Gordon et al. (2016) could not 
attribute the adverse events as a result of corticosteroid use. 
There existed differences among the studies that may have influenced the end 
results.  There were some differences in type of corticosteroid and administration method.  
Although five studies, Sprung et al. (2008), Arabi et al. (2010), Gordon et al. (2014), Lv 
et al. (2017), and Venkatesh et al. (2018), used the same corticosteroid, hydrocortisone, 
the dosages and timing of administration may have varied.  Sprung et al. (2008) and 
Gordan et al. (2014) used 50 mg dosage boluses and the same administration method and 
the drug was tapered after five days.  Arabi et al. (2010) used the same dosage, although 
tapering only occurred once shock was resolved.  Lv et al. (2017) and Venkatesh et al. 
(2018) used the same dosage of 200 mg/d as a continuous infusion.  Lv et al. (2017) 
tapered the drug once vasopressors were discontinued whereas Venkatesh et al. (2018) 
discontinued it after seven days or at ICU discharge.  The study conducted by Annane et 
al. (2018) used fludrocortisone in addition to hydrocortisone.  The hydrocortisone was 
administered as a 50 mg intravenous bolus every 6 hours and fludrocortisone was given 
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as a 50 µg tablet through a nasogastric tube once daily in the morning.  These were 
administered for seven days without tapering. 
The study by Gordon et al. (2016) had a key difference in treatment method that 
could have impacted end results.  The Gordon et al. (2016) study was the only study that 
did not use norepinephrine as the primary vasopressor.  Here, vasopressin was used as the 
primary vasopressor instead of norepinephrine.  Although vasopressin is not 
recommended as the initial vasopressor in septic shock, one of the primary objectives in 
this study was to test the interaction between vasopressin and corticosteroids.  All other 
treatment was based on the Surviving Sepsis Campaign Guidelines at the time the study 
was conducted. 
Next, summary and conclusions will be addressed. 
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Summary and Conclusions 
 Sepsis is a major concern in hospitals that results in a high mortality (Center for 
Disease Control [CDC)], 2017) and increased health care costs (Pfuntner, Weir, & 
Steiner, 2013).  Its most severe form, septic shock, has been the focus of groups such as 
the Surviving Sepsis Campaign.  A widely used adjunctive in the treatment of septic 
shock is corticosteroids.  The use of intravenous corticosteroids has been thought to 
improve the insufficient adrenal function of critically ill patients experiencing septic 
shock (Gupta & Ba, 2008).  There have been disagreements on the efficacy of 
corticosteroids in decreasing mortality in septic shock patients (Lv et al., 2017).  The 
Surviving Sepsis Campaign has cited corticosteroid use as a weak recommendation due 
to contradictory results of prior studies showing either reduction or no difference in 
mortality rates (Rhodes et al., 2017).  Since the latest recommendation in 2016, studies 
have been published that may provide new evidence on the effects of corticosteroids on 
mortality in adult patients with septic shock.  Furthermore, the widespread use of the 
guidelines by medical care providers in hospitals has decreased variances in treatment 
methods that may have existed in past randomized control trials.  
The purpose of this systematic review was to examine whether the use of 
corticosteroids in septic shock impacts overall mortality in adult patients.  The CINAHL, 
PubMed, OVID, and Cochrane Library databases were used to conduct a comprehensive 
search on this topic.  The PRISMA 27-item checklist and four-phase diagram (Moher et 
al., 2009) were utilized in the search process to ensure a thorough selection of studies.  
This search strategy ultimately resulted in six randomized control trials to be used in this 
systematic review.  Pertinent data was extracted and organized using two data collection 
tables produced by this author (Appendices D1-6 and E1-6).  The quality of each study 
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was assessed using the Critical Appraisal Skills Programme (CASP) Randomized Control 
Trial Checklist (Appendix F).  Cross analysis of the studies was conducted utilizing the 
chart depicted in Appendix G.  This chart recorded the primary objective of mortality rate 
at day 28 as well as the secondary endpoints of resolution of shock, vasopressor usage, 
and length of stay in the ICU and hospital. 
The randomized control trials conducted by Sprung et al. (2008), Arabi et al. 
(2010), Gordon et al. (2014), Lv et al. (2017), and Venkatesh et al. (2018) showed 
corticosteroids did not have an effect on mortality in adult patients with septic shock.  
There was no significant difference between corticosteroid and placebo groups in 28-day 
mortality (Appendix G).  The Annane et al. (2018) study was the only one of the six 
studies that demonstrated a decrease in mortality at day 28 in the corticosteroid group 
compared to the placebo group.  The most significant difference between these two 
conflicting results was that the Annane et al. (2018) study utilized fludrocortisone in 
addition to hydrocortisone.  The other studies used only hydrocortisone as the drug of 
choice.  It is important to note there existed some variations among the studies: Arabi et 
al. (2010) used only patients with cirrhosis; Gordon et al. (2014) used vasopressin instead 
of norepinephrine as the primary vasopressor; and Venkatesh et al. (2018) used only 
patients who were ventilated and did not receive etomidate.  Even with these differences 
among studies, each study’s intervention and control groups were alike regarding patient 
characteristics and both groups received the same treatment method. 
There was faster shock reversal in patients receiving corticosteroids in the Arabi 
et al. (2010) and Venkatesh et al. (2018) studies.  Sprung et al. (2008) and Lv et al. 
(2017) did not find a significant difference in the two groups, although Sprung et al. 
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(2008) did report a shorter median time until reversal of shock in the corticosteroid 
group.  The remaining studies did not report this endpoint.  Results of four studies by 
Arabi et al. (2010), Gordon et al. (2014), Lv et al. (2017), and Annane et al. (2018) 
displayed more vasopressor-free days or less days on a vasopressor in the hydrocortisone 
group than the placebo group.  The other two studies did not investigate this endpoint.  In 
terms of LOS in the ICU or hospital, the Sprung et al. (2008), Arabi et al. (2010), and Lv 
et al. (2017) studies did not find any difference among the two study groups.  The only 
significant finding was attained by Venkatesh et al. (2018); these authors reported a 
shorter time to ICU discharge in the hydrocortisone group.  This secondary endpoint was 
not studied in the Gordon et al. (2014) or Annane et al. (2018) trials.  The action of 
corticosteroids on patient’s suppressed HPA axis could explain the quicker resolution of 
shock and decreased vasopressor usage in the corticosteroid groups of the studies.  Their 
anti-inflammatory properties may assist in reducing shock time.  Also, corticosteroids’ 
effects of increasing the body’s sensitivity to catecholamines, like norepinephrine, may 
decrease time and amount of vasopressor usage. 
The most common adverse event attributed to the use of corticosteroids was 
hyperglycemia.  This was documented in the randomized control trials by Sprung et al. 
(2008), Arabi et al. (2010), Venkatesh et al. (2018), and Annane et al. (2018).  Other 
more prominent adverse events included superinfection and hypernatremia in Sprung et 
al. (2008) as well as gastrointestinal bleeding in Arabi et al. (2010).  The Lv et al. (2017) 
study did not report adverse events and the study by Gordon et al. (2016) could not 
attribute the adverse events as a result of corticosteroid use.  These adverse events could 
possibly have occurred in patients with high risk conditions.  A patient with a history of 
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uncontrolled diabetes or with multiple gastrointestinal bleedings may have a higher 
propensity of these adverse events occurring when receiving corticosteroids.  The studies 
did not provide information on whether these events occurred in such patients. 
There existed some limitations in this systematic review.  First, there were only 
six studies that met the inclusion and exclusion criteria, which may affect  
generalizability.  Second, although the primary aim of researching mortality was 
achieved, not all studies reported the same secondary endpoints.  There also existed 
limitations among the six studies in this systematic review.  Some studies (Arabi et al., 
2010; Lv et al., 2017) reported a single center setting which may affect generalizability.  
Three studies (Sprung et al., 2008; Gordon et al., 2014;  Lv et al., 2017) reported a small 
sample size resulting in a limited power to detect differences in the measured clinical 
outcomes.  All the studies reported power except Lv et al. 2017.  Here, the authors 
believed the study to be underpowered based on the recruitment of patients with lower 
mortality (original sample size calculation based on control mortality of 60%, but their 
study’s control 28-day mortality was almost half).  The Arabi et al. (2010) study did not 
achieve their intended sample size, although they did not report this as a limitation.  The 
limited power in these studies may affect generalizability as well.  This means these trials 
demonstrated no significant difference between the groups being studied or they failed to 
detect a difference due to the lack of power.  The Sprung et al. (2008) and Gordon et al. 
(2014) studies stated there were crossovers from the placebo group to the hydrocortisone 
group, meaning these patients received open-label corticosteroids.  The authors stated 
that this was unlikely to have an effect on the outcomes. 
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Despite the limitations mentioned, this systematic review provided sufficient 
evidence to draw a conclusion.  The majority of studies in the systematic review did not 
show an impact on overall mortality between the use of corticosteroids and placebo in 
adult patients with septic shock.  The limitations previously mentioned must be taken into 
consideration.  The four studies that were under-powered could have failed to detect a 
difference between the corticosteroid and placebo groups.  Also, two studies used a single 
center setting to conduct their trial.  The generalizability should be applied with caution 
considering these two factors.  Further studies that are adequately powered using multiple 
centers are required in order to provide more statistically significant data and clinical 
importance.  Future studies with a power of 80% would be sufficient considering any rise 
in power could be difficult since it would require increased sample sizes and study costs.  
Additional studies using fludrocortisone should be conducted as well.  The study by 
Annane et al. (2018) was the only study that used this corticosteroid in addition to 
hydrocortisone and the only study demonstrating a decrease in mortality rates.  In spite of 
these results, fludrocortisone cannot be singly attributed to decreased mortality rates.  
More studies using this corticosteroid, while also using adequate power and multiple 
centers, would provide supplemental data on the impact of corticosteroids on mortality in 
adult patients experiencing septic shock. 
The achievement of the primary aim in this systematic review in combination 
with the comparison of the secondary endpoints results in recommendations and 
implications that can be made for the advanced practice nurse in the clinical setting.  
Recommendations and implications for advanced practice will be discussed in the next 
section. 
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Recommendations and Implications for Advanced Nursing Practice 
   Septic shock is a condition with a high mortality rate and high cost for healthcare 
institutions.  Advanced practice nurses (APNs) are increasingly becoming an integral part 
of healthcare teams.  It should be an expectation for all APNs to stay informed on the 
most current evidence-based results and incorporate them into their practice.  This review 
was able to contribute to evidence-based knowledge and provided an opportunity to guide  
APNs in making more informed decisions. 
The results of this systematic review demonstrate that the use of corticosteroids in 
patients with septic shock cannot be strongly recommended.  Five of the six studies in the 
review showed no improvement in mortality in this population; only one study by 
Annane et al. (2018) showed a decrease in mortality.  It is important to note that mortality 
did not increase in any study and therefore the use of corticosteroids should not be 
disregarded as an option when managing care for a patient with septic shock.  Advanced 
practice nurses should take this into consideration when contemplating using 
corticosteroids in patients with septic shock. 
This systematic review generated valuable information and evidence on whether 
the use of corticosteroids in septic shock impacts overall mortality in adult patients.  The 
review shed light on the latest results of randomized control trials on this topic.  Current 
practice leaves it up to the discretion of the provider to use corticosteroids in this patient 
population.  It is sometimes used as a last-ditch effort to save the patient when 
hemodynamic parameters fail to improve with other interventions.  The information from 
this systematic review can be utilized to potentially improve the care that APNs provide 
as well as to teach student and novice nurse practitioners.  The APN should be aware of 
the limitations of this systematic review and the research studies, as mentioned 
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previously, that affect generalizability.  Nevertheless, the use of the latest research should 
guide the APN in making informed decisions and should be the standard in which care is 
provided. 
The secondary outcomes also need to be considered.  Advanced practice nurses 
need to be cognizant of the adverse events that could occur with corticosteroid 
administration.  Patients with past medical histories of brittle diabetes, gastrointestinal 
bleeding or hypernatremia likely would potentially suffer from worse outcomes if given 
corticosteroids.  One must be mindful of these unique patient characteristics so that the 
appropriate care can be optimized.  Caution should be taken in such patients as 
administration of corticosteroids would require closer monitoring and may necessitate 
additional resources.  For example, when using corticosteroids, an insulin drip may be 
required for labile glucoses in patients with diabetes.  Being able to recognize these 
differences and applying research results when suitable is the critical thinking that should 
be expected of APNs. 
The resolution of shock and decreased vasopressor use could be an incentive in 
using corticosteroids.  Furthermore, the possibility of decreased length of stay in the 
intensive care unit and hospital are other benefits.  Venkatesh et al. (2018) mention the 
overall cost-effectiveness of hydrocortisone in patients with septic shock should be 
assessed.  This would align with healthcare’s recent approaches in providing better care 
at a lower cost.  More research needs to be conducted to provide additional data regarding 
this topic.   
Advanced practice nurses are in prime position to be a part of research teams to 
investigate further the effect of corticosteroids on mortality in septic shock patients.  The 
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limitations described earlier identify areas in which future studies can be improved: larger 
sample sizes with adequate power and more centers used.  The limitations also provide an 
area requiring further investigation which is the effect of fludrocortisone on mortality in 
this selected patient population.  Other areas of research include focusing on the 
relationship between corticosteroid use and shock reversal, vasopressor use, or ICU and 
hospital length of stay.  Qualitative research questions could also be explored, such as 
differences in patient and family satisfaction with hospitalization after corticosteroid use 
or patient’s perception of quality of life.  Septic shock guideline adherence by providers 
is another area of qualitative research that could be investigated.  The APN can be 
involved in conducting such research that could deliver key data resulting in changes in 
clinical practice. 
The information from this systematic review also has implications for education 
and training.  The education and training of future APNs should embrace the most current 
research available.  Informing students of results such as those presented in this review 
will deliver fundamental information that shapes practice. 
Results of this review should also be discussed with staff nurses and other 
members of the interdisciplinary team.  Staff nurses spend more time at the patient’s 
bedside than any other provider.  Staff nurses who are aware of the potential risk of 
adverse events can provide more vigilance during corticosteroid administration and 
thereby alert the medical team to minimize the effects of adverse events or prevent them 
from occurring. 
Current guidelines recommend corticosteroids in septic shock patients only if 
hemodynamics stability is not achieved with fluid resuscitation or vasopressors.  The 
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review of the most recent randomized control trials included in this systematic review 
does not suggest changes be made to this recommendation.  These results should be used 
as a supplemental resource to assist the APN in clinical decision making.  Advance 
practice nurses should also be attentive to the factors the lead to septic shock.  This 
attention to clinical prevention has the potential to greatly reduce the number of patients 
who develop this deadly condition.  Policies regarding central line-associated blood 
stream infections, catheter-associated blood stream infections, and surgical site infections 
should be carefully followed.  Adhering to guidelines on the management of conditions 
such as pneumonia, burns, and acute pancreatitis can also prevent development of septic 
shock.  It is important to prevent infections in patients with weakened immune systems 
such as those receiving long-term steroid treatment and chemotherapy as well as patients 
with long-term health conditions like diabetes and cirrhosis.  Being aware of these patient 
populations and providing appropriate teaching can prevent sepsis that could eventually 
lead to septic shock. 
Septic shock is a condition that has detrimental effects on patients and healthcare 
overall.  Measures must be taken to prevent mortality and any negative consequences that 
may result.  Awareness of the latest research on the impact of corticosteroids on mortality 
in adult patients with septic shock contributes to the knowledge APNs require to improve 
and deliver the best care for their patients. 
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Appendix A 
 
 
Check List for Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
(Moher et al., 2009) 
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Appendix B 
 
 
Flow diagram for preferred reporting items for systematic reviews and meta-analyses 
(Moher et al., 2009) 
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Appendix C 
 
Flow diagram for preferred reporting items for systematic reviews and meta-analyses 
(Moher et al., 2009) 
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Appendix D 
 
D1: Data Collection Tool 1 
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., … Briegel, J. (2008). Hydrocortisone therapy  
for patients with septic shock. The England Journal of Medicine, 358(2), 111-124. 
Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
To evaluate the 
efficacy and safety of 
low-dose 
hydrocortisone in 
patients with septic 
shock – in particular, 
patients who had a 
response to a 
corticotropin test. 
Multicenter, randomized, 
double-blind, placebo-
controlled study. 
 
Patients were enrolled from 
March 2002 to November 2005 
at 52 ICUs in 9 countries. 
 
Inclusion criteria: 18 years or 
older, clinical evidence of 
infection, evidence of a 
systemic response to infection, 
the onset of shock within the 
previous 72 hours, and 
hypoperfusion or organ 
dysfunction attributable to 
sepsis. 
 
Exclusion criteria: underlying 
disease with a poor prognosis, a 
life expectancy of less than 24  
500 patients enrolled, 
although 1 withdrew 
consent. Divided into 2 
groups: hydrocortisone 
group (251 patients) and 
placebo group (248 
patients). 
 
Mean age: hydrocortisone 
group = 63 + 14, placebo 
group = 63 + 15. 
 
Male gender: 
hydrocortisone group = 
166 (66%), placebo group 
= 166 (67%). 
 
SOFA score: 
hydrocortisone group = 
10.6 + 3.4, placebo group = 
10.6 + 3.2. 
The primary 
endpoint was death 
at 28 days in 
patients who did 
not have a 
response to 
corticotropin. 
 
Secondary 
endpoints included 
rates of death at 28 
days in patients 
who had a 
response to 
corticotropin and 
overall, in the 
ICU, in the 
hospital, the rate of 
shock reversal, and 
LOS in the ICU 
and hospital. 
Hydrocortisone 
was given as a 50 
mg bolus 
intravenously 
every 6 hours for 5 
days, then tapered 
to 50 mg every 12 
hours for days 6 to 
8, 50 mg every 24 
hours for days 9 to 
11, and then 
stopped. 
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Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
 hours, immunosuppression, and 
treatment with long-term 
corticosteroids within the past 6 
months or short-term 
corticosteroids within the last 4 
weeks. 
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D2: Data Collection Tool 1 
Arabi Y. M., Aljumah A., Dabbagh O., Tamim H. M., Rishu A. H., Al-Abdulkareem, A., … Cherfan A. (2010). Low-dose 
hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial. Canadian Medical Association Journal, 
182(18), 1971-7. doi: 10.1503/cmaj.090707 
Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
Examine the effect of 
low-dose 
hydrocortisone in 
patients with cirrhosis 
who presented with 
septic shock. 
 
Randomized double-blind 
placebo-controlled trial. 
900-bed tertiary care academic 
hospital on a 21-bed medical-
surgical ICU. 
 
Inclusion criteria: patients aged 
18 years or older with liver 
cirrhosis who presented with 
septic shock within 72 hours of 
the onset of hypotension. 
 
Exclusion criteria: hemorrhagic 
shock, known adrenal 
insufficiency, any prior 
systemic steroid usage, 
contraindications for systemic 
steroids, post-cardiac arrest, and 
do-not-resuscitate status. 
 
Full dose of study drug was 
continued until shock  
140 patients screened, 75 
enrolled and randomly 
allocated. 60 patients were 
enrolled within 24 hours 
after the onset of shock and 
71 within 48 hours. 
 
Mean age: hydrocortisone 
group = 60.6 + 12.6, 
placebo group = 59.3 + 
12.2 
 
Female(%): hydrocortisone 
group = 17(44%), placebo 
group = 16(44%) 
 
Mean SOFA score: 
hydrocortisone group = 
14.6 + 3.7, placebo group = 
14.3 + 3.7  
 
The primary 
outcome was 28-
day all-cause 
mortality. 
 
Secondary 
outcomes included 
ICU-specific and 
hospital-specific 
mortality, shock 
reversal, and 
vasopressor-free 
days. 
 
Participants 
received 
intravenous bolus 
injections every 
six hours of 5 mL 
of normal saline 
containing 50 mg 
of hydrocortisone 
Once shock 
resolved, the dose 
was reduced by 1 
mL every 2 days 
until 
discontinuation. 
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Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
 resolution, which was defined 
as blood pressure stability 
(MAP>65) without 
vasopressors for 24 hours. 
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D3: Data Collection Tool 1 
Study: Gordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby, D., & Brett, S. J. (2014). The interaction of  
vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine 42(6), 1325-1333. 
Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
To test for an 
interaction between 
vasopressin and 
corticosteroids in 
septic shock. 
Prospective open-label 
randomized controlled pilot 
trial. 
 
Conducted between October 
2010 and March 2012 at four 
adult ICUs in London teaching 
hospitals. 
 
Inclusion criteria: adult patients 
(>16 yrs) who had septic shock 
requiring vasopressors despite 
adequate IV fluid resuscitation. 
 
Exclusion criteria: patients who 
received a previous continuous 
infusion of vasopressors during 
current hospitalization, an 
ongoing requirement for 
systemic steroids, end-stage 
renal failure, known mesenteric 
ischemia, Raynaud’s 
phenomenon, systemic sclerosis  
61 adult patients who had 
septic shock. 
 
Male gender: 
hydrocortisone group = 
58%, placebo group = 
60%. 
 
Mean age: hydrocortisone 
group = 61, placebo group 
= 60. 
 
Mean APACHE II score: 
hydrocortisone group = 19, 
placebo group = 20. 
The primary 
outcome was the 
difference in 
plasma 
vasopressin 
concentration 
between the two 
groups. 
 
Secondary 
outcomes included 
28-day, ICU, and 
hospital mortality. 
Hydrocortisone 
phosphate was 
given as a 50mg 
IV bolus every 6 
hours for 5 days, 
every 12 hours for 
3 days, and then 
once daily for 3 
days. 
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Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
 or other vasospastic disease, 
ongoing treatment for an acute 
coronary syndrome, death 
anticipated within 24 hours, 
known pregnancy, 
hypersensitivity to any study 
drugs, or enrollment in another 
trial that may interact with 
study drugs. 
 
Patients were assigned to one of 
two groups: vasopressin and 
hydrocortisone or vasopressin 
and placebo. 
All patients were planned to 
receive vasopressin (titrated to 
0.06U/min as the initial 
vasopressor. Once max infusion 
rate reached, patients received 
either hydrocortisone or 
placebo. 
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D4: Data Collection Tool 1 
 
 
 
 
Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. (2017). Early initiation of low-dose hydrocortisone treatment for septic shock in 
adults: A randomized clinical trial. American Journal of Emergency Medicine, 35(12), 1810-1814.  
doi: 10.1016/j.ajem.2017.06.004 
Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
To assess the 
importance of early 
initiation of low dose 
hydrocortisone. 
A placebo-controlled, 
randomized clinical trial. 
 
From Sept 2015 to Sept 2016, 
118 patients admitted to the 35-
bed ICU of the Subei People’s 
Hospital were recruited. 
 
Inclusion criteria: age 18 yrs or 
older, onset of septic shock 
within 6 hours. 
 
Exclusion criteria: systemic 
corticosteroid therapy within 
the last 3 months, high-dose 
steroid therapy, 
immunosuppression, refusal of 
the attending staff or patient 
family. 
118 patients 
Gender: male/female = 
70/48 
 
Age (mean + SD): 
hydrocortisone group = 
68.8 + 12.6,  
placebo group = 64.8 + 
16.7 
 
SOFA score (mean + SD): 
hydrocortisone group = 
11.9 + 3.3, placebo group = 
9.9 + 3.0 
28-day mortality Hydrocortisone 
administered 200 
mg/d as a 
continuous 
infusion for 6 
days, then tapered 
off. Once all 
vasopressors 
discontinued, the 
taper protocol was 
initiated (half dose 
for 5 days, then 
quarter dose for 3 
days, then 
stopped) 
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D5: Data Collection Tool 1 
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., … Myburgh, J. (2018). Adjunctive 
glucocorticoid therapy in patients with septic shock. The New England Journal of Medicine, 379(9), 797-808. 
Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
To determine whether 
hydrocortisone 
reduces mortality 
among patients with 
septic shock. 
Investigator-initiated, 
international, pragmatic, 
double-blind, parallel-group, 
randomized controlled trial. 
 
From March 2013 through 
April 2017, a total of 3,800 
patients underwent 
randomization at 69 med-surg 
ICUs. 
 
Compared intravenous 
infusions of hydrocortisone 
with matched placebo in 
patients with septic shock who 
were undergoing mechanical 
ventilation in an ICU. 
 
Inclusion criteria:  Adults (>18 
years), undergoing mechanical 
ventilation, documented 
suspicion of infection, met >2 
criteria of the systemic  
3,658 enrolled patients: 
1,832 in hydrocortisone 
group, 1,826 in placebo 
group. 
 
Age (mean + SD): 
hydrocortisone group = 
62.3 + 14.9,  
placebo group = 62.7 + 
15.2 
 
Male gender: 
hydrocortisone group = 
60.4%, placebo group = 
61.3% 
 
APACHE II median score: 
hydrocortisone group = 
24.0, placebo group = 23.0 
Primary outcome 
was death from 
any cause at 90 
days. 
 
Death from any 
cause at 28 days 
was a secondary 
outcome. 
Hydrocortisone at 
a dose of 200mg 
per day 
administered by 
means of 
continuous 
intravenous 
infusion over a 
period of 24 hours 
for a maximum of 
7 days or until ICU 
discharge. 
Masked vial 
reconstituted  to 
produce a 
concentration of 
1mg per milliliter. 
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Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
 inflammatory response 
syndrome, and who had been 
treated with vasopressors or 
inotropic agents for a minimum 
of 4 hours up to and at the time 
of randomization. 
 
Exclusion criteria: If patients 
were likely to receive 
glucocorticoids for an 
indication other than septic 
shock, had received etomidate, 
were considered to be likely to 
die from a pre-existing disease 
within 90 days, had treatment 
limitations in place, or had met 
all the inclusion criteria for 
more than 24 hours. 
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D6: Data Collection Tool 1 
 
 
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P., Siami, S., … Bellissant, E. (2018). Hydrocortisone plus 
fludrocortisone for adults with septic shock. New England Journal of Medicine, 378(9), 809-818. 
doi: 10.1056/NEJMoa1705716 
Purpose Study Design Sample Demographics Mortality Endpoint Corticosteroid 
To evaluate the effect 
of hydrocortisone plus 
fludrocortisone 
therapy versus placebo 
in patients with septic 
shock. 
 
(Originally purpose 
was to evaluate effect 
of hydrocortisone plus 
fludrocortisone 
therapy, drotrecogin 
alpha, the combination 
of the three drugs, or 
their respective 
placebos but 
drotrecogin alpha 
removed from market 
during trial). 
A multicenter, double-blind, 
randomized trial with two-
group parallel design. 
 
34 participating centers. 
Patients recruited from Sept 2, 
2008 through June 23, 2015. 
 
Inclusion criteria: indisputable 
or probable septic shock for less 
than 24 hours. 
 
Exclusion criteria: presence of 
septic shock for at least 24 
hours, a high risk of bleeding, 
pregnancy or lactation, 
underlying conditions that could 
affect short-term survival, or 
previous treatment with 
corticosteroids. 
1,241 patients: 626 
hydro/fludro group, 614 
placebo group 
 
Age (mean + SD): 
hydrocortisone group = 66 
+ 14, placebo group = 66 + 
15 
 
Male gender: hydro/fludro 
group = 402 (65.5%), 
placebo group = 424 
(67.7%) 
 
SOFA score: hydro/fludro 
group = 12 + 3, placebo 
group = 11 + 3 
90-day all-cause 
mortality. 
 
Secondary 
outcomes included 
all-cause mortality 
at ICU discharge, 
hospital discharge, 
and day 28, and 
vasopressor free 
days by day 28. 
Hydrocortisone 
was administered 
as a 50-mg 
intravenous bolus 
every 6 hours, and 
fludrocortisone 
was given as a 50- 
µg tablet through a 
nasogastric tube 
once daily in the 
morning. This was 
administered for 7 
days without 
tapering. 
62 
 
Appendix E 
 
E1: Data Collection Tool 2 
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., … Briegel, J. (2008). Hydrocortisone therapy  
for patients with septic shock. The England Journal of Medicine, 358(2), 111-124. 
 
Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
Exact placebo not 
mentioned. Vials 
containing 
placebo were 
identical to those 
containing 
hydrocortisone. 
86 (34.3%) 78 (31.5%) There was no significant 
difference between the two 
study groups in the rate of 
death at 28 days among overall 
patients and those with and 
without a response to 
corticotropin. 
 
Overall: hydrocortisone group 
= 34.3% (95% CI., 28.3 to 
40.2), placebo group = 31.5% 
(95%, 25.5 to 37.3; P = 0.51). 
 
No corticotropin response: 
hydrocortisone group = 39.2% 
(95% CI, 30.5 to 47.9), 
placebo group = 36.1% (95% 
CI, 26.9 to 45.3; P=0.69).  
 
Authors note a lack of adequate power 
since only 500 patients were enrolled 
instead of the projected 800. They 
attributed this to slow recruitment, 
termination of funding, and expiration 
date of the trial drug. 
 
21 patients received open-label 
corticosteroids (4.2%). Authors 
believed this was unlikely to have an 
effect on the outcome. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
(No corticosteroid) 
   Corticotropin response: 
hydrocortisone group = 28.8% 
(95% CI, 20.6 to 37.0), 
placebo group = 28.7% (95% 
CI, 21.2 to 36.3; P = 1.00). 
 
ICU discharge 28-day 
mortality:  hydrocortisone 
group = 40.6%, placebo group 
= 36% (P=0.31). 
 
Hospital discharge 28-day 
mortality: hydrocortisone 
group = 44.6%, placebo group 
= 40.8 (P=0.47). 
 
Reversal of shock was similar 
among all patients. 
Hydrocortisone group = 
79.7%, placebo group = 74.2% 
(P=0.18). 
Median time until reversal of 
shock was shorter in the 
hydrocortisone group: 
hydrocortisone group = 3.3 
days, placebo group = 5.28 
days. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
(No corticosteroid) 
   LOS was similar in both 
groups. 
 
In ICU: hydrocortisone group 
= 19 + 31, placebo group = 18 
+ 17 (P=0.51). 
In hospital:  hydrocortisone 
group = 34 + 41, placebo 
group = 34 + 37 (P=0.47). 
 
In the hydrocortisone group 
there was an increased 
incidence of superinfections 
(new episodes of sepsis or 
septic shock), hyperglycemia, 
and hypernatremia. 
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E2: Data Collection Tool 2 
Arabi Y. M., Aljumah A., Dabbagh O., Tamim H. M., Rishu A. H., Al-Abdulkareem, A., … Cherfan A. (2010). Low-dose 
hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial. Canadian Medical Association Journal,  
182(18), 1971-7. doi: 10.1503/cmaj.090707 
Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
Normal saline 
(placebo) given in 
same manner as 
hydrocortisone. 
 
33 (85%) 26 (72%) There was no significant 
difference between the 
hydrocortisone and placebo 
groups in 28-day mortality (33 
[85%] v. 26 [72%], RR 1.117, 
95% CI 0.92-1.49, p=0.19). 
 
There was no difference 
between the two groups in ICU 
(P=0.86) or hospital LOS 
(P=0.90). 
ICU mortality was 24 (62%) in 
hydrocortisone group and 24 
(67%) in placebo group 
(P=0.64). 
Hospital mortality was 34 
(87%) in hydrocortisone group 
and 32 (89%) in placebo group 
(P=0.82). 
 
Limitations included the setting of the 
study at a single-centre  which may 
affect its generalizability. 
 
The length of the randomization 
window was long at 72 hours. 
 
Etomidate was used in some patients 
which has been shown to cause adrenal 
suppression. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
   The hydrocortisone showed 
improved hemodynamic 
parameters. 
Shock reversal: hydrocortisone 
group = 24 (62%), placebo 
group 14 (39%) (P=0.05). 
Mean vasopressor-free days: 
hydrocortisone group = 6.8, 
placebo group = 5.6 (P=0.54). 
 
Hydrocortisone was associated 
with higher rates of severe 
hyperglycemia: hydrocortisone 
group = 34 (87%), placebo 
group = 25 (69%). 
Also, there was a significant 
increase in the risk of 
gastrointestinal bleeding: 
hydrocortisone group = 13 
(33%), placebo group = 4 
(11%). 
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E3: Data Collection Tool 2 
Gordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby, D., & Brett, S. J. (2014). The interaction of 
vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine 42(6), 1325-1333. 
Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
Placebo was 0.5 
mL 0.9% saline 
given in same 
manner as 
hydrocortisone. 
7 (23%) 7 (23%) There was no difference in 
mortality rates. 
28-day mortality: 
hydrocortisone group = 23%, 
placebo group = 23% (-0.01*). 
ICU mortality: hydrocortisone 
group = 23%, placebo group = 
27% (-0.04*). 
Hospital mortality: 
hydrocortisone group = 26%, 
placebo group = 30% (-0.04*). 
*Difference in proportions: 
(vaso + hydro) – (vaso + 
placebo).   
 
Patients in the hydrocortisone 
group were weaned off 
vasopressin more quickly with 
a 3.1 day (P=0.001) shorter 
duration of vasopressin 
infusion and a halving of the  
The study was prospectively powered 
to detect a difference in plasma 
vasopressin levels at single point after 
reaching maximum rate of vasopressin 
infusion and corticosteroid 
administration. Not all patients reached 
the max vasopressin rate even though 
additional existing catecholamines 
were weaned off quickly. This reduced 
the sample size and potential power in 
the analysis of plasma levels 
 
There were 5 crossovers from the 
placebo group to hydrocortisone group 
due to refractory shock (although 
results remained unchanged). 
 
The use of 61 patients resulted in 
limited power to detect differences in 
clinical outcomes measures. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
   total dose (P=0.001) of 
vasopressin required than 
placebo group. Hydrocortisone 
= 2.5 + 2.4 days of 
vasopressor, placebo group = 
2.8 + 4 days. 
 
There was no difference in 
plasma vasopressin levels. 
 
14 adverse events reported 
although none attributed 
directly to hydrocortisone. 
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E4: Data Collection Tool 2 
Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. (2017). Early initiation of low-dose hydrocortisone treatment for septic shock in 
adults: A randomized clinical trial. American Journal of Emergency Medicine, 35(12), 1810-1814.  
doi: 10.1016/j.ajem.2017.06.004 
Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
(No corticosteroid) 
Normal saline 
(Administration 
procedure same 
as 
hydrocortisone) 
23 (39.7%) 19 (31.7%) There were no significant 
differences in 28-day 
(P=0.365) or hospital all-cause 
mortality length of stay in the 
ICU or hospital between 
patients treated with 
hydrocortisone or placebo. 
 
In-hospital mortality: 
hydrocortisone group = 23 
(39.7%),  
placebo group = 19 (31.7%, 
P=0.365) 
 
LOS in ICU, days: 
hydrocortisone group = 10.9 + 
17.5, 
placebo group = 10.2 + 13.1 
(P=0.799) 
 
Only short-term outcomes, 28-day and 
in-hospital mortality, were collected 
and therefore any long-term difference 
between treatment groups cannot be 
assessed. 
 
The study was likely to be 
underpowered to detect a statistically 
significant difference by the 
recruitment of patients with lower 
mortality. Authors note the original 
calculated sample size was based on a 
control mortality of 60% using findings 
from a large prior study, but this 
study’s control mortality was about 
half. 
 
The sample size was relatively small, 
and only one center was involved, 
which may affect its generalizability. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
   LOS in hospital, days: 
hydrocortisone group = 23.7 + 
36.8, 
placebo group = 21.7 + 21.7 
(P=0.711) 
Shock reversal was similar in 
both groups. Hydrocortisone 
group = 65.6%, placebo group 
= 70.0% (P=0.602) 
Early administration of 
hydrocortisone enabled earlier 
titration off vasoactive therapy. 
Norepinephrine duration: 
hydrocortisone group = 2.5 + 
2.4, placebo group = 2.8 + 4.0 
(P=0.639) 
The early initiation of low-
dose hydrocortisone did not 
decrease the risk of mortality 
or the length of stay in the ICU 
or hospital in adults with septic 
shock. 
 
These findings do not support 
the use of hydrocortisone in 
these patients. 
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E5: Data Collection Tool 2 
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., … Myburgh, J. (2018). Adjunctive  
glucocorticoid therapy in patients with septic shock. The New England Journal of Medicine, 379(9), 797-808. 
Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
Masked vial 
reconstituted to 
produce an 
equivalent 
volume of 
placebo (200ml). 
(Administration 
procedure same 
as 
hydrocortisone) 
410 (22.3%) 448 (24.3%) Among patients with septic 
shock undergoing mechanical 
ventilation, a continuous 
infusion of hydrocortisone did 
not result in lower 90-day 
mortality than placebo 
(P=0.50). 
 
There was no significant 
difference in mortality at 28 
days (P=0.13). 
Hydrocortisone group = 410 
(22.3%), placebo group = 448 
(24.3%) 
 
The resolution of shock was 
shorter (days) in the 
hydrocortisone group 
(P<0.001). 
Hydrocortisone group = 3, 
placebo group = 4 
. 
The authors did not identify adverse 
events themselves. Data on adverse 
events were judged by the treating 
clinicians thought to be related to the 
trial regimen. This judgement was not 
adjudicated. This may weaken 
inferences about adverse events. 
 
Data were not collected regarding all 
possible secondary infections. Only 
bacteremia and fungemia data was 
recorded. 
 
The appropriateness of antibiotic 
therapy was not adjudicated. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
   Patients receiving 
hydrocortisone had a shorter 
time to ICU discharge (days) 
(P<0.001). 
Hydrocortisone group = 10, 
placebo group = 12 
 
There was a higher percentage 
of adverse events in the 
hydrocortisone vs placebo 
group (1.1% vs 0.3%, 
P=0.009) the most prevalent 
being hyperglycemia 
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E6: Data Collection Tool 2 
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P., Siami, S., … Bellissant, E. (2018). Hydrocortisone plus 
fludrocortisone for adults with septic shock. New England Journal of Medicine, 378(9), 809-818. 
doi: 10.1056/NEJMoa1705716 
Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
Respective 
placebos given in 
same manner. 
Hydrocortisone 
placebo = 
mannitol 
(133.6mg), 
disodium 
phosphate 
(8.73mg), and 
sodium phosphate 
(0.92mg). 
Fludrocortisone 
placebo =  
microcrystalline 
cellulose 
(59.098mg), 
magnesium 
stearate (0.6mg), 
and colloidal  
207 (33.7%) 244 (38.9%) The relative risk of death was 
0.88 (95% CI, 0.78 to 0.99) in 
favor of hydro/fludro therapy. 
Death occurred in 43% in 
hydro/fludro group and 49.1% 
in placebo group. 
 
Mortality at day 28 was 33.7% 
for the hydro/fludro group and 
38.9% for the placebo group 
(P=0.06). 
 
Mortality was significantly 
lower in hydro/fludro group 
than placebo group at ICU 
discharge (35.4% vs 41%, 
P=0.04) and hospital discharge 
(39% vs 45.3%, P=0.02). 
 
 
No limitations were reported by the 
authors in this study. 
 
The trial was suspended twice: 
First, from October 2011 to May 2012 
after the withdrawal of drotrecogin 
alpha from the market. 
Second, from July 2014 to October 
2014 at the request of the data and 
monitoring board to check the quality 
of the trial drugs and reported serious 
adverse events. 
 
After drotrecogin alpha withdraw, the 
trial continued as a two-group parallel 
design. 
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Identified Placebo Mortality Rate at Day 28 Key Findings Limitations 
Corticosteroid Placebo 
 (No corticosteroid) 
anhydrous silica 
(0.3mg). 
  The hydro/fludro group had 
more vasopressor-free days (17 
+ 11) than placebo group (15 + 
11) by day 28 (P<0.001). 
 
The risk of secondary 
infection, GI bleeding, or 
neurological events was not 
significantly higher in the 
hydro/fludro group although 
the risk of hyperglycemia was 
significantly higher in the 
hydro/fludro group. 
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Appendix F1 
Study: Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., … 
Briegel, J. (2008). Hydrocortisone therapy for patients with septic shock. The England 
Journal of Medicine, 358(2), 111-124. 
Section A: Are the results of the trial valid? Yes Can’t 
tell 
No 
     1. Did the trial address a clearly focused issue? ü   
     2. Was the assignment of patients to treatments  
     randomised? 
ü   
     3. Were all of the patients who entered the trial properly  
     accounted for at its conclusion? 
One patient withdrew consent after randomization. 
  ü 
     4. Were patients, health workers and study personnel  
     ‘blind’ to treatment? 
Of note, 4.4% of the hydrocortisone group and 4.0% of the 
placebo group received open-label corticosteroids after study 
enrollment due to allergic reactions, laryngeal edema, 
bronchospasm, brain edema, replacement of long-term 
corticosteroid therapy whose history was unknown at 
enrollment, acute respiratory distress syndrome, and septic 
shock. 
ü   
     5. Were the groups similar at the start of the trial? 
 
ü   
     6. Aside from the experimental intervention, were the  
     groups treated equally? 
ü   
Section B: What are the results? 
 
     7. How large was the treatment effect? 
The mortality rate at 28 days was 34.3% (86/251 deaths) in the hydrocortisone group 
and 31.5% (78/248 deaths) in the placebo group. 
     8. How precise was the estimate of the treatment effect? 
A sample size of 800 patients was needed to achieve a statistical power of 80% to 
detect an absolute decrease in mortality of 10% from an existing death rate of 50% in 
patients who did not have a response to corticotropin (40% of total group). 
Section C: Will the results help locally? Yes Can’t 
tell 
No 
     9. Can the results be applied to the local population, or in  
     your context? 
ü   
     10. Were all clinically important outcomes considered? 
 
ü   
     11. Are the benefits worth the harms and costs? 
 
ü   
Critical Appraisal Skills Programme (CASP) Randomised Controlled Trials Checklist 
(2018) 
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Appendix F2 
Study: Arabi Y. M., Aljumah A., Dabbagh O., Tamim H. M., Rishu A. H., Al-
Abdulkareem, A., … Cherfan A. (2010). Low-dose hydrocortisone in patients with 
cirrhosis and septic shock: A randomized controlled trial. Canadian Medical  
Association Journal, 182(18), 1971-7. doi: 10.1503/cmaj.090707 
Section A: Are the results of the trial valid? Yes Can’t 
tell 
No 
     1. Did the trial address a clearly focused issue? 
 
ü   
     2. Was the assignment of patients to treatments  
     randomised? 
ü   
     3. Were all of the patients who entered the trial properly  
     accounted for at its conclusion? 
ü   
     4. Were patients, health workers and study personnel  
     ‘blind’ to treatment? 
Of note, blinding was opened for one patient at the request of 
the primary physician, but the therapy (placebo) was 
continued as planned per the study protocol. 
ü   
     5. Were the groups similar at the start of the trial? ü   
     6. Aside from the experimental intervention, were the  
     groups treated equally? 
Five patients in the placebo group were given rescue 
corticosteroids for the treatment of life-threatening 
hypotension and were considered crossovers. 
  ü 
Section B: What are the results? 
 
     7. How large was the treatment effect? 
The mortality rate at 28 days was 85% (33/39 deaths) in the hydrocortisone group and 
72% (26/36 deaths) in the placebo group. 
     8. How precise was the estimate of the treatment effect? 
Based on an estimated baseline 28-day mortality of 90% and an estimated absolute 
risk reduction of 20%, 75 patients were required in each group using a two-sided type 
I error of 5% and power of 80%. 
A planned interim analysis was performed after randomly allocating 75 patients and 
found a trend towards excess 28-day mortality with the hydrocortisone group. At this 
point the trial was stopped since it was highly unlikely that a significant treatment 
benefit would be evident if the trial were completed to the targeted sample size. 
Section C: Will the results help locally? Yes Can’t 
tell 
No 
     9. Can the results be applied to the local population, or in  
     your context? 
ü   
     10. Were all clinically important outcomes considered? 
 
ü   
     11. Are the benefits worth the harms and costs? ü   
 
77 
 
Appendix F3 
Study: Gordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby, 
D., & Brett, S. J. (2014). The interaction of vasopressin and corticosteroids in septic  
shock: a pilot randomized controlled trial. Critical Care Medicine 42(6), 1325-1333. 
Section A: Are the results of the trial valid? Yes Can’t 
tell 
No 
     1. Did the trial address a clearly focused issue? 
 
ü   
     2. Was the assignment of patients to treatments  
     randomised? 
ü   
     3. Were all of the patients who entered the trial properly  
     accounted for at its conclusion? 
Two patients met exclusion criteria after randomization, but 
before administration of the study drug.  
 ü  
     4. Were patients, health workers and study personnel  
     ‘blind’ to treatment? 
ü   
     5. Were the groups similar at the start of the trial? 
 
ü   
     6. Aside from the experimental intervention, were the  
     groups treated equally? 
Due to emergency situations, not all patients received 
vasopressin as the initial vasopressor. 30% received 
vasopressin as the initial vasopressor and 50% were 
transitioned to vasopressin within the first 4 hours of the 
onset of shock. Also, eleven patients did not reach maximum 
vasopressin requirements so did not receive the study drug. 
  ü 
Section B: What are the results? 
 
     7. How large was the treatment effect? 
The mortality rate at 28 days was 23% (7/31 deaths) in the hydrocortisone group and 
23% (7/30 deaths) in the placebo group. 
     8. How precise was the estimate of the treatment effect? 
30 patients were required in each treatment group in order to study the primary 
outcome of the difference in plasma vasopressin concentration between groups. 
The group sizes were calculated in order to detect a 33 pmol/L difference in 
vasopressin levels at 6-12 hours post corticosteroid administration assuming a SD of 
45 pmol/L with a significance level of 0.05 and 80% power. 
 
Section C: Will the results help locally? Yes Can’t 
tell 
No 
     9. Can the results be applied to the local population, or in  
     your context? 
ü   
     10. Were all clinically important outcomes considered? 
 
ü   
     11. Are the benefits worth the harms and costs? ü   
78 
 
Appendix F4 
Study: Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. (2017). Early initiation of low-
dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial. 
American Journal of Emergency Medicine, 35(12), 1810-1814.  
doi: 10.1016/j.ajem.2017.06.004 
Section A: Are the results of the trial valid? Yes Can’t 
tell 
No 
     1. Did the trial address a clearly focused issue? 
 
ü   
     2. Was the assignment of patients to treatments  
     randomised? 
ü   
     3. Were all of the patients who entered the trial properly  
     accounted for at its conclusion? 
ü   
     4. Were patients, health workers and study personnel  
     ‘blind’ to treatment? 
ü   
     5. Were the groups similar at the start of the trial? 
The initial SOFA score was higher in the hydrocortisone 
group compared to the placebo group and was statistically 
significant (P<0.001). 
 
  ü 
     6. Aside from the experimental intervention, were the  
     groups treated equally? 
ü   
Section B: What are the results? 
 
     7. How large was the treatment effect? 
The mortality rate was 39.7% (23 deaths) in the hydrocortisone group and 31.7% (19 
deaths) in the placebo group. 
 
     8. How precise was the estimate of the treatment effect? 
The study was likely to be underpowered to detect a statistically significant difference 
by the recruitment of patients with lower mortality.  The original sample size collection 
was based on a control mortality of 60% originating from the findings of the largest 
prior study, but the control 28-day mortality in this study was almost half that. 
 
Section C: Will the results help locally? Yes Can’t 
tell 
No 
     9. Can the results be applied to the local population, or in  
     your context? 
ü   
     10. Were all clinically important outcomes considered? 
 
ü   
     11. Are the benefits worth the harms and costs? 
 
ü   
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Appendix F5 
Study: Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., … 
Myburgh, J. (2018). Adjunctive glucocorticoid therapy in patients with septic shock. 
The New England Journal of Medicine, 379(9), 797-808. 
Section A: Are the results of the trial valid? Yes Can’t 
tell 
No 
     1. Did the trial address a clearly focused issue? 
 
ü   
     2. Was the assignment of patients to treatments  
     randomised? 
ü   
     3. Were all of the patients who entered the trial properly  
     accounted for at its conclusion? 
Of the 3800 patients enrolled, 114 patients either withdrew or 
did not have informed consent obtained, and 28 patients were 
lost to follow-up at 90 days. 
  ü 
     4. Were patients, health workers and study personnel  
     ‘blind’ to treatment? 
ü   
     5. Were the groups similar at the start of the trial? 
 
ü   
     6. Aside from the experimental intervention, were the  
     groups treated equally? 
ü   
Section B: What are the results? 
 
     7. How large was the treatment effect? 
The mortality rate at 28 days was 22.3% (410/1832 deaths) in the hydrocortisone 
group and 24.3% (448/1826 deaths) in the placebo group. 
 
     8. How precise was the estimate of the treatment effect? 
A population of 3800 patients provided the trial with 90% power to detect an absolute 
difference of 5% in 90-day all-cause mortality from an estimated baseline mortality of 
33%, at an alpha level of 0.05. This allowed for a rate of withdrawal and loss to 
follow-up of 1%. 
 
Section C: Will the results help locally? Yes Can’t 
tell 
No 
     9. Can the results be applied to the local population, or in  
     your context? 
ü   
     10. Were all clinically important outcomes considered? 
 
ü   
     11. Are the benefits worth the harms and costs? 
 
ü   
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Appendix F6 
Study: Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P., 
Siami, S., … Bellissant, E. (2018). Hydrocortisone plus fludrocortisone for adults with 
septic shock. New England Journal of Medicine, 378(9), 809-818. 
doi: 10.1056/NEJMoa1705716 
Section A: Are the results of the trial valid? Yes Can’t 
tell 
No 
     1. Did the trial address a clearly focused issue? 
 
ü   
     2. Was the assignment of patients to treatments  
     randomised? 
ü   
     3. Were all of the patients who entered the trial properly  
     accounted for at its conclusion? 
ü   
     4. Were patients, health workers and study personnel  
     ‘blind’ to treatment? 
ü   
     5. Were the groups similar at the start of the trial? 
 
ü   
     6. Aside from the experimental intervention, were the  
     groups treated equally? 
ü   
Section B: What are the results? 
 
     7. How large was the treatment effect? 
The mortality rate at 28 days was 33.7% (207/1241 deaths) in the hydrocortisone 
group and 38.9% (244/1241 deaths) in the placebo group. 
 
     8. How precise was the estimate of the treatment effect? 
A 90-day mortality of 45% among patients with septic shock was anticipated. 320 
patients were needed in each group to detect an absolute difference of 10% in 90-day 
mortality (α=0.05 and power at 95%). 
Section C: Will the results help locally? Yes Can’t 
tell 
No 
     9. Can the results be applied to the local population, or in  
     your context? 
ü   
     10. Were all clinically important outcomes considered? 
 
ü   
     11. Are the benefits worth the harms and costs? 
 
ü   
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Appendix G 
Cross Study Analysis 
 Author, Year Mortality Rate at  
Day 28 
Resolution of Shock Vasopressor Usage Length of Stay (LOS) 
ICU Hospital 
1 Sprung et al., 
2008 
Corticosteroid: 34.3% 
Placebo: 31.5 
 
P=0.51 
Corticosteroid: 79.7% 
Placebo: 74.2% 
 
P=0.18 
 
Median time to 
Reversal (days) 
Corticosteroid: 3.3 
Placebo: 5.28 
Not reported Corticosteroid: 
19+31 
Placebo:18+17 
 
P=0.51 
Corticosteroid: 
34+41 
Placebo: 34+37 
 
P=0.47 
2 Arabi et al., 
2010 
Corticosteroid: 85% 
Placebo: 72% 
 
P=0.19 
 
Corticosteroid: 62% 
Placebo: 39% 
 
P=0.05 
Vasopressor-free days 
Corticosteroid: 6.8 
Placebo: 5.6 
 
P=0.54 
Corticosteroid: 9.2 
Placebo: 9.6 
 
P=0.86 
Corticosteroid: 
27.2 
Placebo: 43.3 
 
P=0.90 
3 Gordon et al., 
2014 
Corticosteroid: 23% 
Placebo: 23% 
Not reported Days on Vasopressor 
Corticosteroid: 2.5+2.4 
Placebo: 2.8+4 
 
P=0.001 
 
 
Not reported Not reported 
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 Author, Year Mortality Rate at  
Day 28 
Resolution of Shock Vasopressor Usage Length of Stay (LOS) 
ICU Hospital 
4 Lv et al., 2017 Corticosteroid: 39.7% 
Placebo: 31.7% 
 
P=0.365 
Corticosteroid: 65.6% 
Placebo: 70.0% 
 
P=0.602 
Days on Vasopressor 
Corticosteroid: 2.5+2.5 
Placebo: 2.8+4.0 
 
P=0.639 
Corticosteroid: 
10.9+17.5 
Placebo: 
10.2+13.1 
 
P=0.799 
Corticosteroid: 
23.7+36.8 
Placebo: 
21.7+21.7 
 
P=0.711 
5 Venkatesh et 
al, 2018 
Corticosteroid: 22.3% 
Placebo: 24.3% 
 
P=0.13 
(Days) 
Corticosteroid: 3 
Placebo: 4 
 
P=<0.001 
Not reported Corticosteroid: 10 
Placebo: 12 
 
P<0.001 
Corticosteroid: 
39 
Placebo: 43 
 
P=0.13 
6 Annane et al, 
2018 
Corticosteroid: 33.7% 
Placebo: 38.9% 
 
P=0.06 
Not reported Vasopressor-free days 
Corticosteroid: 17+11 
Placebo: 15+11 
 
P<0.001 
Not reported Not reported 
 
